***CURRICULUM VITAE***

***STEPHEN THOMAS BARTLETT, M.D.***

***Vice President***

***OSF Healthcare, Surgery Service Line***

***Medical Director Academic Affairs***

***OSF Healthcare System***

***Clinical Professor of Surgery***

***Division of Transplantation***

***University of Illinois, Chicago***

**DATE: February 15, 2023**

**PERSONAL INFORMATION**

**Office Address:**

Ministry Headquarters

124 SW Adams

Peoria, IL 61602

[stephen.t.bartlett@osfhealthcare.org](mailto:stephen.t.bartlett@osfhealthcare.org)

mobile 410-215-4467

|  |  |  |
| --- | --- | --- |
| **Home Address:** | | 5321 Mapleleaf Court |
|  |  | Rockford, Illinois 61108 |
| **EDUCATION** | |  |
| **University:** |  | Johns Hopkins University |
|  |  | B.A. (with Honors) Chemistry |
| B.A. degree | | Baltimore, Maryland  09/1971-05/1975 |
| **Medical School:** | | University of Chicago Pritzker |
|  |  | School of Medicine |
| M.D. degree | | Chicago, Illinois  09/1975-06/1979 |
| **Internship:** | | University of Pennsylvania |
|  |  | Department of Surgery |
|  |  | Philadelphia, Pennsylvania  06/1979-06/1980 |

|  |  |  |
| --- | --- | --- |
| Stephen Thomas Bartlett, M.D. | | Page 2 |
|  | |  |
| **Residency:** | | University of Pennsylvania |
|  |  | Department of Surgery |
|  |  | Philadelphia, Pennsylvania  07/1980-06/1985 |
| **Fellowship:** | | Northwestern University |
|  |  | Division of Vascular Surgery |
|  |  | Chicago, Illinois  07/1985-06/1986 |
| **Research Fellowships:** | |  |
|  |  | National Science Foundation Fellowship |
|  |  | Department of Chemistry |
|  |  | University of Delaware 06/1974-09/1974 |
|  |  | Harrison Department of Surgical Research Fellow |
|  |  | University of Pennsylvania 07/1981-06/1985 |
|  |  | Measey Research Fellow |
|  |  | University of Pennsylvania 07/1981-06/1985 |
|  |  | Conrad Jobst Fellow 07/1985-06/1986 |
|  |  | Vascular Surgical Research |
|  |  | Northwestern University |
| **BOARD CERTIFICATION** | |  |
|  |  | American Board of Surgery |
|  |  | Certificate #031321  Initial Certification 04/09/1986  Recertification 10/20/1995  Recertification 10/04/2004  Recertification 12/13/2014  Certification Valid till 12/31/2026 |
|  |  | American Board of Surgery |
|  |  | Certificate of Special Qualifications in General Vascular Surgery |
|  |  | Certificate #100002  Initial Certification 05/16/1988  Recertification 10/18/1996  Recertification 10/10/2007  Recertification 09/16/2016  Certification Valid till 12/31/2028 |
|  |  |  |
|  |  |  |



|  |  |  |  |
| --- | --- | --- | --- |
| Stephen Thomas Bartlett, M.D. | | | Page 3 |
|  | | |  |
| **MEDICAL LICENSURES** | | |  |
| Expires 12/31/2020 |  |  | Commonwealth of Pennsylvania (MD024497E) |
| Expires 07/31/2023 |  |  | State of Illinois (036-070805) |
| Expires 11/30/2021 |  |  | State of California (G58749-retired status) |
| Expires 09/30/2022 |  |  | State of Maryland (D41332) |
| Expires 06/30/2022 |  |  | State of West Virginia (19999 inactive) |
| Expires 03/31/2021 |  |  | State of Delaware (C1-0006408 inactive) |
| Expires 06/30/2021 |  |  | State of New Jersey (25MA07335900-inactive) |
| **FACULTY POSITIONS** | | |  |
| July 1986-June 1990 |  | | Assistant Professor of Surgery |
|  |  |  | University of California, Davis |
| July 1990-March 1991 | | | Associate Professor of Surgery, with tenure |
|  |  |  | University of California, Davis |
| March 1991-June 1996 | | | Associate Professor of Surgery, with tenure |
|  |  |  | Chief, Section of Transplantation |
|  |  |  | University of Maryland School of Medicine |
|  |  |  | Baltimore, Maryland |
| July 1996-December, 2018 | | | Professor of Surgery, with tenure |
|  |  |  |  |
|  |  |  | University of Maryland School of Medicine |
| July 1996-December, 2018 | | | Professor of Medicine |
|  |  |  | University of Maryland School of Medicine |
| February 2003-October 2009 | | | Barbara Baur Dunlap Professor of Surgery |
| January 2003-October 2003 | | | Vice Chairman, Department of Surgery |
|  |  |  | University of Maryland Medical System |
| October 2003-December 2004 | | | Acting Chairman, Department of Surgery |
|  |  |  | University of Maryland School of Medicine |
| December 2004-Dec 31, 2017 | | | Chairman, Department of Surgery |
|  |  |  | University of Maryland School of Medicine |
|  |  |  | Surgeon-in-Chief |
|  |  |  | University of Maryland Medical Center |



January 1, 2018-December 31, 2018 Peter Angelos Distinguished Professor of Surgery

January 10, 2020-present Clinical Professor of Surgery University of Illinois, Chicago

**POSITIONS, UNIVERSITY OF MARYLAND MEDICAL SYSTEM**

July 1, 2010-December, 2018

System Surgeon-in-Chief

University of Maryland Medical System

Report: Robert Chrencik Pres., CEO

Stephen Thomas Bartlett, M.D.



Page 4

**POSITIONS, UNIVERSITY OF MARYLAND MEDICAL SYSTEM con’t**

|  |  |  |
| --- | --- | --- |
| March 2012- July 2015: | Senior Vice President for System Integration | |
|  | Report: Robert Chrencik, President and CEO, University of Maryland | |
|  | Medical System | |
| July 2015- December, 2018: | Executive Vice President for System Integration | |
|  | Report: Robert Chrencik, President and CEO, University of Maryland | |
|  | Medical System | |
| October 1, 2017 – January 1, 2019 (retirement) | Executive Vice President, Chief Medical Officer & Surgeon-In-Chief | |
|  | Report: Robert Chrencik, President and CEO, University of Maryland Medical System | |
| **VASCULAR SURGERY ASSOCIATES**  February 1, 2019- August 11, 2019 **Partner,** Vascular Surgery Associates  August 13, 2019- present  Consultant, Vascular Surgery Associates  **OSF Healthcare St. Anthony Hospital Vice President and Chief Medical Officer**  **08/12/2019-present** |  | |
| **MAJOR ACADEMIC AND ADMINISTRATIVE TASKS** | | |
| July 1991-December 2004 | Medical Director |  |
|  | Transplant Resource Center of Maryland | |
|  | Baltimore, Maryland | |
| March 1991-June 2004 | Head, Division of Transplantation | |
|  | University of Maryland School of Medicine | |
| 2005 | Chair, Department of Anesthesiology Search Committee | |
| July 2007-June 2009 | President-Elect, Medical Staff | |
|  | University of Maryland Medical Center | |
| July 2009-June 2011 | President, Medical Staff | |
|  | University of Maryland Medical Center | |
| 2011 – 2013 | Immediate Past President and Chair of Nominating Committee, Medical | |
|  | Staff, University of Maryland Medical Center | |
| 2012 | Chair, Obstetric and Gynecology Chair Search Committee | |
| 2014 | Co-Chair IPITA Opinion Leaders Consensus Conference on | |
|  | Beta Cell Replacement | |
|  | Oxford, UK May7-9, 2014 | |

**HONORS AND AWARDS**

The Barbara Baur Dunlap Professor of Surgery

The Peter Angelos Distinguished Professor

2013 Sante Kidney Champion (National Kidney Foundation)

University System of Maryland Board of Regents 2009 Faculty Award, Public Service University System of Maryland Board of Regents 2014 Faculty Award, Research

Stephen Thomas Bartlett, M.D.



Page 5

**PROFESSIONAL MEMBERSHIPS**

American College of Physician Executives

American College of Surgeons

American College of Surgeons Professional Association

American College of Surgeons, Maryland Chapter

American Diabetes Association

American Medical Association

American Society of Transplant Surgeons

American Surgical Association

Association for Academic Surgery

Baltimore County Medical Association

Chesapeake Vascular Society

International Pancreas and Islet Transplant Association

International Society for Cardiovascular Surgery

MedChi, The Maryland State Medical Society

Monthly Medical Reunion

Society for Surgery of the Alimentary Tract

Society of University Surgeons

Southwestern Surgical Congress

Surgical Biology Club II

Transplantation Society

University of Maryland Surgical Society

|  |  |  |  |
| --- | --- | --- | --- |
| **GRANT REVIEW** | | |  |
| 1997 |  |  | National Institutes of Health/National Institutes of Allergy and Infectious |
|  |  |  | Disease Transplantation Tolerance Study Group |
| 1999 |  |  | NIH/NIAID Special Emphasis Panel: Collaborative Network for Clinical |
|  |  |  | Research of Immune Tolerance |
| 2001 |  |  | NIH/National Institute of Diabetes and Digestive and Kidney Diseases |
|  |  |  | Special Emphasis Panel ZDK1 GRB-1 CR2 B, Pancreas Transplant |
|  |  |  | Database |
| 2001- 2004 |  |  | Juvenile Diabetes Foundation – Regular Member Immunology Study |
|  |  |  | Section |
| **EDITORIAL BOARD** | |  |  |
| 2000-present | | | *Graft* |
| 2001-2004 |  |  | *Transplantation* |
| 2001-2003 |  |  | *American Journal of Transplantation* |

Stephen Thomas Bartlett, M.D.



Page 6

|  |  |  |  |
| --- | --- | --- | --- |
| **EDITORIAL REVIEW** | | | *Transplantation* |
|  |  |  | *Journal Surgical Research* |
|  |  |  | *Archives of Surgery* |
|  |  |  | *Annals of Surgery* |
|  |  |  | *Clinical Transplantation* |
|  |  |  | *American Journal of Transplantation* |
|  |  |  | *J. Vascular Surgery* |
|  |  |  | *Surgery* |
|  |  |  | *Archives of Surgery* |
| **LOCAL COMMITTEES** | | |  |
| 06/04 |  |  | Board of Trustees, Transplant Resource Center of Maryland |
| 12/03 |  |  | Region Two Representative, Kidney/Pancreas Transplantation Committee |
|  |  |  | United Network for Organ Sharing |
| 12/03 |  |  | Chairman, Perioperative Executive Committee, University of Maryland |
| 12/03 |  |  | Appointed Member, National Impact Committee, National Kidney |
|  |  |  | Foundation |
| 11/03 |  |  | Executive Committee, School of Medicine Council, University of |
|  |  |  | Maryland |
| 09/03 |  |  | Board of Trustees, University Physicians, Incorporated |
| 09/03 |  |  | Clinical Affairs Advisory Committee, University Physicians, |
|  |  |  | Incorporated |
| 01/07 |  |  | Executive Committee, University Physicians Incorporated |
| 2009-2011 |  |  | President, Medical Staff at University of Maryland Medical Center |
| 2011 |  |  | Co-Chair, University of Maryland Baltimore Strategic Plan |
| 2011 |  |  | Chair, OB, GYN & Reproductive Sciences Search Committee |

**NATIONAL and INTERNATIONAL APPOINTMENTS**

Board of Directors, National Kidney Foundation (2001-2007)

Physician Advisory Board, National Kidney Foundation, Maryland

Honorary Board of Directors, National Kidney Foundation, Hawaii

Chesapeake Transplant Society, President

Pancreas Club Advisory Council

American Society of Transplant Surgeons/Committee on Government Relations

ASTS/Membership Committee

ASTS/Chairman of the Bylaws Committee

**NATIONAL and INTERNATIONAL APPOINTMENTS cont’d**

UNOS, Organ Procurement Organization Committee

Councillor, International Society Pancreas and Islet Transplantation

UNOS, Regional Representative of the Kidney and Pancreas Transplantation Committee ASTS Ethics Committee

President, International Pancreas and Islet Transplant Association, 2009-2011

Immediate Past President, International Pancreas and Islet Transplant Association, 2011-2013, IPITA is a section of the Transplantation Society

Stephen Thomas Bartlett, M.D.



Page 7

**GRANT SUPPORT**

* Bartlett, PI: 2017 - 2021

Cardiac Xenotransplantation: Translation from Baboon to Man United Therapeutics $23,900,000

* MR120023P1 Bartlett (PI),Barth co-PI, Rodriguez co-PI: $2,532,424 10/01/2013–9/30/2017 in cost free extension

Department of Defense (DoD), Clinical and Rehabilitative Medicine Research program (CRMRP) “Upregulation of Bone Marrow Compartment-Mediated Immunomodulation for Vascularized Composite

Allografts”

The principal objective of this project is to hone vascularized composite allotransplantation (VCA) into a useful therapeutic option for patients in need of advanced tissue reconstruction and replacement."

* W81XWH-13-AFIRM-IIRP Barth (PI); Bartlett, S.T. Co-PI and, Rodriguez E.D. Co-PI:

$1,493,000 / 7/1/2013-6/30/2018

COO of AFIRM-WRC, Wake Forest School of Medicine

The goals of this study are to investigate whether the immunologic benefit of VBM in VCA is quantitative or qualitative, to determine the mechanisms of the immunologic benefit of VBM and to perform a clinical trial of maxillofacial VCA transplantation with large volume VBM, T cell depletion, and steroid weaning.

|  |  |  |
| --- | --- | --- |
| **GRANT SUPPORT** |  |  |
| **NIH:** | |  |
| NIH U01 A152748 | | Redfield (PI) |
| NIH | | $59,466 |
| 3/01/04 – 6/30/11 | | Effort: .12 P.M. |

Solid Organ Transplantation in HIV: Multi-Site Study

The major goal is to study renal transplantation in patients with healthy HIV infection.

Role: Co-Investigator

NIH 5M01RR0116500-05 3/1/2006-2/28/2007 Islet Cell Study

Bartlett (PI)/Reece (overall PI)

The major goal of this grant was the study of the causes of recurrent autoimmunity in islet transplants and to establish a clinical islet transplant program. This grant is a small subproject of a General Clinical Research Center (GCRC) grant with the Dean of the School of Medicine as overall PI.

NIH 5M01RR0116500-04: Bartlett (PI)/Wilson (overall PI)

3/1/2005-2/28/2006

Islet Transplant Alone (ITA) for Type 1 DiabetesThe major goal of this grant was a clinical trial of islet transplantation for patients with Type 1 diabetes. This grant is a small subproject of a General Clinical Research Center (GCRC) grant with the Dean of the School of Medicine as overall PI.

Stephen Thomas Bartlett, M.D. Page 8



NIH 5M01RR0116500-03: Bartlett (PI)/Wilson (overall PI)

Islet Transplant Alone (ITA) for Type 1 Diabetes

The major goal this grant was a clinical trial of islet transplantation for patients with Type 1 diabetes. This grant is a small subproject of a General Clinical Research Center (GCRC) grant with the Dean of the School of Medicine as overall PI.

NIH 2S07RR005684-20: Bartlett (PI)

Recurrent Diabetes in Pancreas Transplants – A Possible Solution

The major goal of this grant was the investigation of recurrent autoimmunity in islet transplants in a BB rat

model.

Role: PI

NIH R21 AG33791: Mullins (PI)

NIH $325,433

9/1/08-7/31/10: Effort: .48 P.M.

Response to Medicare Reimbursement Policy Changes by Minority and all ESRD Patients The major goal is to expand knowledge of racial disparities in ESRD patients’ access to kidney transplantation.

Role: Co-Investigator

**Federal:**

N00014-10-1-0868: Bartlett (PI)

06/1/2010-05/31/12: Effort: 2.4 P.M.

Office of Naval Research: $3,187,200

Chimerism and tolerance in composite tissue transplantation

The major goal of this project is to develop a therapeutic strategy that will allow widespread application of

composite tissue allotransplantation (CTA) as a therapy to treat and return to service injured military

personnel.

Role: PI

N00014-07-1-0766: Bartlett (PI)

Office of Naval Research: $2,887,350

7/30/2008-03/21/2010: 1.8 calmos

Composite Tissue Transplantation for Civilian and Combat Casualties

The major goal is designed to determine the immune suppression strategy needed for long-term survival of composite tissue transplants in a pre-clinical primate model. Role: PI

R39OT03408: Bartlett (PI)

HRSA: $638,089

8/1/2006/7/31/2008: 12 calmos

Social and Behavioral Interventions to Increase Organ and Tissue Donation

The major goal is to evaluate the impact of increased education on kidney donors attending out-patient

dialysis.

Role: PI

Stephen Thomas Bartlett, M.D.



Page 9

**Federal con’t:**

N00014-06-1-0298: Bartlett (PI)

Office of Naval Research: $877,677

11/20/2006-12/30/2007

Studies in Massive Tissue Transfer for Combat Casualties

The major goal is to define technical and immunologi8c barriers to composite tissue transplants. Role: PI

N00014-06-1-018: Bartlett (PI)

Office of Naval Research: $1,011,810

11/28/2005-3/31/2007

Studies in Massive Tissue Transfer for Combat Casualties

The major goal is to define technical and immunologic barriers to composite tissue transplants. Role: PI

N00014-04-1-0821: Bartlett (PI)

Office of Naval Research: $1,218,284

9/30/2004-3/31/2006

New Immune Strategies for Composite Tissue Transplantation for the Treatment of Combat Casualties with Massive Tissue Loss

The major goal is to define technical and immunologic barriers to composite tissue transplants. Role: PI

N00014-03-1-0125: Bartlett (PI)

Office of Naval Research: $1,448,000

11/26/2003-12/31/2005

New Immune Strategies for Composite Tissue Transplantation for the Treatment of Combat Casualties with Massive Tissue Loss

The major goal is to define technical and immunologic barriers to composite tissue transplants. Role: PI

N0014-03-1-0611: Bartlett (PI)

Office of Naval Research: $953,310

4/07/2003-12/31/2003

New Immune Strategies for Composite Tissue Transplantation for the Treatment of Combat Casualties with Massive Tissue Loss

The major goal is to define technical and immunologic barriers to composite tissue transplants.

N00014-01-1-1014: Bartlett (PI)

Office of Naval Research: $1,447,500

8/01/2001-12/31/2002

New Immune Strategies for Composite Tissue Transplantation for the Treatment of Combat Casualties with Massive Tissue Loss

The major goal is to define technical and immunologic barriers to composite tissue transplants.

Stephen Thomas Bartlett, M.D.



Page 10

Role: PI

**Other:**

1-2008-149: Bartlett (PI)

Juvenile Diabetes Research Foundation: $495,000

3/1/2008-2/28/2011 / Effort: 1.8 P.M.

Mechanism of Abrogation of Autoimmunity in an Islet Graft Model

The major goal is to elucidate the mechanism for the protection of islet cell transplants with donor

pancreatic lymph node cells.

Role: PI

Diabetes Research and Education Foundation

1987-1989

$30,000 (total award)

Principal Investigator

Diabetes Treatment Centers of America Foundation

1987-1989

$40,000 (total award)

Principal Investigator

A multi-center randomized comparative study comparing Sandimmune Oral solution and OG-325 Oral

solution in the prevention of renal allograft rejection

1993-1994

SANDOZ Pharmaceuticals

$101,000 (total award)

Co-Principal Investigator

SANDOZ Neoral Conversion Study

1996-1998

$63,000

Principal Investigator

A double-blind, comparative study of the effect of two dose levels of Sirolimus versus Azathioprine,

administered concomitantly with standard immunosuppressive therapy in renal allograft recipients

1996-1997

Wyeth-Ayerst

Protocol #0468E1-301-US

$195,146

Principal Investigator

A multicenter, randomized, open-label trial of a regimen of Simulect with early Neoral versus Atgam with delayed Neoral in de novo kidney transplant recipients 1997-2000

Novartis Pharmaceuticals Corporation

$111,555

Principal Investigator

Stephen Thomas Bartlett, M.D. Page 11



**Other con’t:**

Thymoglobulin dose escalating pharmacokinetic and pharmacodynamic evaluation in adult renal allograft

recipients

1998-1999

SangStat

$151,494

Co-Principal Investigator

Human Islet Transplantation Research Program

1998-2000

Weinberg Foundation

$250,000

Principal Investigator

Serial color flow doppler ultrasound evaluation of venaflow and standard ePTFE vascular grafts used in

hemodialysis applications

1998-2003

IMPRA, Inc.

$26,000

Co-Principal Investigator

Fenoldopam with early CSA/Tacrolimus in renal delayed graft function: A multicenter, randomized,

double-blinded, placebo-controlled trial

1999

Neurex Corporation

$42,040

Primary Investigator

A prospective, randomized, multicenter trial of early corticosteroid cessation vs. long term maintenance

corticosteroid therapy in primary renal allograft recipients treated with Tacrolimus and mycophenolate

mofetil

1999-2000

Fujisawa USA, Inc.

$500,000

Principal Investigator

Comparative trial of two daclizumab dosing strategies vs. no induction treatment (protocol# 7915) 1999-2004

Roche Pharmaceuticals, Inc.

$117,750

Co-Principal Investigator

A three-year, randomized multicenter, double-blind, double-dummy, parallel group study of the efficacy and

safety of SDZ RAD tablets versus mycophenolate mofetil as part of triple immunosuppressive therapy in de

novo renal transplant recipients

1999-2004

Novartis Pharmaceuticals Corporation

$230,432

Stephen Thomas Bartlett, M.D.



Page 12

Co-Principal Investigator

**Other cont’d**

The economic, clinical outcomes model of laparoscopic technology 2000-2003

Roche Pharmaceuticals

$130,000 – FY01

$550,000 – FY02

Principal Investigator

Transplant biopsy acquisition & storage system

2001-2002

Wyeth-Ayerst Laboratories

Project #010691

$ 100,000

Principal Investigator

Research Program – Bringing a cure for Juvenile Diabetes 2002-2004

The Harry and Jeanette Weinberg Foundation, Inc.

Grant #: B03-073

$504,000

Principal Investigator

Human Islet Transplantation Research

1998-2004

Fujisawa Corporation

$500,000

Principal Investigator

Stephen Thomas Bartlett, M.D.



Page 13

**PUBLICATIONS**

**JOURNAL ARTICLES - (Referred)**

1. Barker, C.F., A. Naji, L.J. Perloff, D.C. Dafoe, and S. Bartlett, *Invited commentary: an overview*

*of pancreas transplantation--biologic aspects.* Surgery, 1982. 92(2): p. 133-7.

1. Barker, C.F., A. Naji, L.J. Perloff, D.C. Dafoe, and S. Bartlett, *Animal models of diabetes and* *immunological problems with islet allografts.* Trans Am Soc Artif Intern Organs, 1982. 28: p.691-9.
2. Kaplan, E.L., S. Bartlett, J. Sugimoto, and A. Fredland, *Relation of postoperative hypocalcemia* *to operative techniques: deleterious effect of excessive use of parathyroid biopsy.* Surgery, 1982.92(5): p. 827-34.
3. Bartlett, S.T., A.S. Jennings, C. Yu, A. Naji, C.F. Barker, and W.K. Silvers, *Influence of* *culturing on the survival of major histocompatibility complex-compatible and -incompatible thyroid grafts in rats.* J Exp Med, 1983. 157(1): p. 348-52.
4. Bartlett, S.T., A. Naji, W.K. Silvers, and C.F. Barker, *Influence of culturing on the functioning of* *major-histocompatibility-complex-compatible and incompatible islet grafts in diabetic mice.* Transplantation, 1983. 36(6): p. 687-90.
5. Kaplan, E.L., J. Sugimoto, S. Bartlett, and A. Fredland, *Postoperative hypocalcemia - its relation* *to operative techniques.* Ann Chir Gynaecol, 1983. 72(3): p. 146-52.
6. Naji, A., W.K. Silvers, S.T. Bartlett, J. Francfort, and C.F. Barker, *Immunologic factors in* *pathogenesis and treatment of human and animal diabetes.* World J Surg, 1984. 8(2): p. 214-20.
7. Silvers, W.K., S.T. Bartlett, H.D. Chen, H.L. Fleming, A. Naji, and C.F. Barker, *Major* *histocompatibility complex restriction and transplantation immunity. A possible solution to the allograft problem.* Transplantation, 1984. 37(1): p. 28-32.
8. Marshall, V., B. Ross, M. Smith, S. Bartlett, and D. Freeman, *Organ and tissue preservation for* *transplantation: monitoring by 31P nuclear magnetic resonance.* Transplant Proc, 1985. 17(2):p. 1693-6.
9. Bartlett, S.T., A.J. Olinde, W.R. Flinn, W.J. McCarthy, 3rd, V.A. Fahey, J.J. Bergan, and J.S. Yao, *The reoperative potential of infrainguinal bypass: long-term limb and patient survival.* J Vasc Surg, 1987. 5(1): p. 170-9.
10. Stept, L.L., W.R. Flinn, W.J. McCarthy, 3rd, S.T. Bartlett, J.J. Bergan, and J.S. Yao, *Technical* *defects as a cause of early graft failure after femorodistal bypass.* Arch Surg, 1987. 122(5): p.599-604.
11. Bartlett, S.T., L.A. Killewich, C. Fisher, and R.E. Ward, *Duplex imaging of in situ saphenous* *vein bypass grafts and late failure reduction.* Am J Surg, 1988. 156(6): p. 484-7.
12. Bartlett, S.T., W.J. McCarthy, 3rd, A.S. Palmer, W.R. Flinn, J.J. Bergan, and J.S. Yao, *Multiple* *aneurysms in Behcet's disease.* Arch Surg, 1988. 123(8): p. 1004-8.
13. Bartlett, S.T., E.S. Woodle, T. Hibler, and R.E. Ward, *Stapled duodenal-cystic anastomosis in* *pancreas transplantation.* Transplantation, 1988. 46(3): p. 460-2.
14. Bartlett, S.T., S.L. Gillison, and D.L. Curry, *The in vitro perfused pancreas: a model for*

*rigorous comparison of pancreatic transplant techniques.* Transplant Proc, 1989. 21(1 Pt 3): p.2820-2.

1. Bartlett, S.T. and R.E. Ward, *Pretransplant hyperthermia promotes permanent survival of* *murine thyroid allografts.* J Surg Res, 1989. 46(4): p. 370-3.

Stephen Thomas Bartlett, M.D.



Page 14

1. Bartlett, S.T. and R.E. Ward, *Donor specific transfusions in rodent pancreatic transplantation.* Transplant Proc, 1989. 21(1 Pt 1): p. 1185-6.
2. Gillison, S.L., S.T. Bartlett, and D.L. Curry, *Synthesis-secretion coupling of insulin. Effect of* *cyclosporin.* Diabetes, 1989. 38(4): p. 465-70.
3. Ward, R.E., S.T. Bartlett, J.O. Koenig, J. Ballenger, J. Neylan, and M. Friend, *The use of duplex* *scanning in evaluation of the posttransplant kidney.* Transplant Proc, 1989. 21(1 Pt 2): p. 1912-6.
4. Bartlett, S.T. and W.E. Dugoni, Jr., *The effect of histocompatibility matching and cyclosporine* *on rat pancreas transplants.* Transplant Proc, 1990. 22(2): p. 741-2.
5. Bartlett, S.T. and W.E. Dugoni, Jr., *Cyclosporine treatment of BB rat pancreas transplant* *recipients: a functional and histologic analysis.* Transplant Proc, 1990. 22(2): p. 736-8.
6. Bartlett, S.T., W.E. Dugoni, Jr., and R.E. Ward, *Improved results with surgical treatment of* *renovascular hypertension: an individualized approach.* J Cardiovasc Surg (Torino), 1990.31(3): p. 351-5.
7. Bartlett, S.T., S.L. Gillison, and D.L. Curry, *Cyclosporine inhibition of insulin secretion: effect*

*of tolbutamide and extracellular calcium concentration.* Transplant Proc, 1990. 22(2): p. 749-53.

1. Bartlett, S.T., S.L. Gillison, B. Dirden, W.E. Dugoni, and D.L. Curry, *A functional comparison of* *pancreas and pancreaticoduodenal transplants.* Transplant Proc, 1990. 22(2): p. 590-2.
2. Dugoni, W.E., Jr. and S.T. Bartlett, *Evidence that cyclosporine prevents rejection and recurrent* *diabetes in pancreatic transplants in the BB rat.* Transplantation, 1990. 49(5): p. 845-8.
3. Dugoni, W.E., Jr., S.T. Bartlett, and R.E. Ward, *A simplified method for bilateral aortorenal* *bypass.* Surg Gynecol Obstet, 1990. 170(2): p. 159-60.
4. Killewich, L.A. and S.T. Bartlett, *The "all-autogenous" tissue policy for infrainguinal* *reconstruction questioned.* Am J Surg, 1990. 160(6): p. 552-4; discussion 554-5.
5. Killewich, L.A., C. Fisher, and S.T. Bartlett, *Surveillance of in situ infrainguinal bypass grafts:* *conventional vs. color flow duplex ultrasonography.* J Cardiovasc Surg (Torino), 1990. 31(5): p.662-7.
6. Thayer, C., S.T. Bartlett, and R.E. Ward, *Increased septic complications with three-drug* *sequential immunosuppression for cadaver renal transplants.* Am J Surg, 1990. 160(6): p. 614-7.
7. Bartlett, S.T. and L.A. Killewich, *Recurrent diabetes in pancreas transplants in the BB rat:* *evidence for a defect extrinsic to the beta cell.* Transplant Proc, 1991. 23(1 Pt 1): p. 689-90.
8. Gillison, S.L., S.T. Bartlett, and D.L. Curry, *Inhibition by cyclosporine of insulin secretion--a* *beta cell-specific alteration of islet tissue function.* Transplantation, 1991. 52(5): p. 890-5.
9. Bartlett, S.T., S.L. Gillison, B. Dirden, and D.L. Curry, *Long-term pancreatic and* *pancreaticoduodenal isografts maintain normal insulin secretory function in Lewis rats.* Transplant Proc, 1992. 24(3): p. 884-5.
10. Schweitzer, E.J., C.B. Drachenberg, and S.T. Bartlett, *Living kidney donor and recipient* *evaluation in Fabry's disease.* Transplantation, 1992. 54(5): p. 924-7.
11. Bartlett, S.T., G.A. Hadley, B. Dirden, E.J. Schweitzer, S. Eans, D. Pham, and C. Sheffield, *Composite kidney-islet transplantation prevents recurrent autoimmune beta-cell destruction.* Surgery, 1993. 114(2): p. 211-7.
12. Drachenberg, C.B., E.J. Schweitzer, S.T. Bartlett, M.T. Behrens, and J.C. Papadimitriou, *Polyarteritis nodosa-like necrotizing vasculitis in Fabry disease.* J Inherit Metab Dis, 1993.16(5): p. 901-2.
13. Keay, S., M.T. Behrens, D. Klassen, M.R. Weir, E. Schweitzer, D. Evans, N.T. Constantine, and S. Bartlett, *Impact asymptomatic HIV-1 infection on renal allograft recipients.* Transplant Proc, 1993. 25(1 Pt 2): p. 1478-80.

Stephen Thomas Bartlett, M.D.



Page 15

1. Schweitzer, E.J. and S.T. Bartlett, *Simultaneous PTFE reconstruction of the external iliac artery* *with kidney transplantation.* Clin Transplant, 1993. 7(2): p. 179-82.
2. Schweitzer, E.J., S.T. Bartlett, S. Keay, G.A. Hadley, J. Cregar, and D.D. Stockdreher, *Impact of* *hepatitis B or C infection on the practice of kidney transplantation in the United States.* Transplant Proc, 1993. 25(1 Pt 2): p. 1456-7.
3. Scott, T.R., S.M. Graham, E.J. Schweitzer, and S.T. Bartlett, *Colonic necrosis following sodium* *polystyrene sulfonate (Kayexalate)-sorbitol enema in a renal transplant patient. Report of a case and review of the literature.* Dis Colon Rectum, 1993. 36(6): p. 607-9.
4. Bartlett, S.T., B. Dirden, E.J. Schweitzer, C. Sheffield, and G.A. Hadley, *Prevention of recurrent* *autoimmune islet transplant destruction by simultaneous kidney transplantation.* TransplantProc, 1994. 26(2): p. 737.
5. Schweitzer, E.J. and S.T. Bartlett, *Wound complications after pancreatic transplantation through* *a kidney transplant incision.* Transplant Proc, 1994. 26(2): p. 461.
6. Sheffield, C.D., G.A. Hadley, B.M. Dirden, and S.T. Bartlett, *Prolonged cardiac xenograft* *survival is induced by intrathymic splenocyte injection.* J Surg Res, 1994. 57(1): p. 55-9.
7. Sheffield, C.D., G.H. Hadley, and S.T. Bartlett, *Xenograft tolerance induced by intrathymic* *spleen cell injection.* Transplant Proc, 1994. 26(3): p. 1204.
8. Bartlett, S.T., T. Chin, B. Dirden, A. Quereshi, and G. Hadley, *Inclusion of peripancreatic lymph* *node cells prevents recurrent autoimmune destruction of islet transplants: evidence of donor chimerism.* Surgery, 1995. 118(2): p. 392-7; discussion 397-8.
9. Bartlett, S.T., E.J. Schweitzer, J.E. Roberts, J.L. Jaekels, G.L. Sandager, L.B. Johnson, and L.A. Killewich, *Early experience with a new ePTFE vascular prosthesis for hemodialysis.* Am J Surg, 1995. 170(2): p. 118-22.
10. Graham, S.M., J.L. Flowers, E. Schweitzer, S.T. Bartlett, and A.L. Imbembo, *Opportunistic* *upper gastrointestinal infection in transplant recipients.* Surg Endosc, 1995. 9(2): p. 146-50.
11. Graham, S.M., J.L. Flowers, E. Schweitzer, S.T. Bartlett, and A.L. Imbembo, *The utility of* *prophylactic laparoscopic cholecystectomy in transplant candidates.* Am J Surg, 1995. 169(1): p.44-8; discussion 48-9.
12. Killewich, L.A., S.O. Pais, G. Sandager, W.R. Flinn, and S.T. Bartlett, *Salvage of renal allograft* *function and lower extremity venous patency with thrombolytic therapy: case report and review of the literature.* J Vasc Surg, 1995. 21(4): p. 691-6.
13. Klassen, D.K., M.R. Weir, E.J. Schweitzer, and S.T. Bartlett, *Isolated pancreas rejection in* *combined kidney-pancreas transplantation: results of percutaneous pancreas biopsy.* TransplantProc, 1995. 27(1): p. 1333-4.
14. Krebs, T., B. Daly, J. Wong, and S. Bartlett, *The magnetic resonance-derived pancreas to psoas* *ratio (PPR): objective and reliable noninvasive diagnosis of pancreatic rejection.* TransplantProc, 1995. 27(6): p. 3034.
15. Krebs, T.L., B. Daly, J.J. Wong, C.C. Chow, and S.T. Bartlett, *Vascular complications of* *pancreatic transplantation: MR evaluation.* Radiology, 1995. 196(3): p. 793-8.
16. Marks, M.J., S.O. Pais, and S.T. Bartlett, *Successful restoration of renal allograft function with* *urokinase thrombolysis in the setting of phlegmasia cerulea dolens.* J Vasc Interv Radiol, 1995.6(2): p. 279-82.
17. Bartlett, S.T., *Pancreatic transplantation after thirty years: still room for improvement.* J Am

Coll Surg, 1996. 183(4): p. 408-10.

1. Bartlett, S.T., A. delaTorre, L.B. Johnson, P.C. Kuo, and E.J. Schweitzer, *Long-term pancreatic* *function: potential benefits.* Transplant Proc, 1996. 28(4): p. 2128-30.

Stephen Thomas Bartlett, M.D.



Page 16

1. Bartlett, S.T., P.C. Kuo, L.B. Johnson, J.W. Lim, and E.J. Schweitzer, *Pancreas transplantation* *at the University of Maryland.* Clin Transpl, 1996: p. 271-80.
2. Bartlett, S.T., E.J. Schweitzer, L.B. Johnson, P.C. Kuo, J.C. Papadimitriou, C.B. Drachenberg, D.K. Klassen, E.W. Hoehn-Saric, M.R. Weir, and A.L. Imbembo, *Equivalent success of* *simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy.* Ann Surg, 1996. 224(4): p. 440-9;discussion 449-52.
3. Drachenberg, C., D. Klassen, S. Bartlett, E. Hoehn-Saric, E. Schweitzer, L. Johnson, M. Weir, and J. Papadimitriou, *Histologic grading of pancreas acute allograft rejection in percutaneous* *needle biopsies.* Transplant Proc, 1996. 28(1): p. 512-3.
4. Drachenberg, C.B., J.C. Papadimitriou, M.R. Weir, D.K. Klassen, E. Hoehn-Saric, and S.T. Bartlett, *Histologic findings in islets of whole pancreas allografts: lack of evidence for recurrent* *cell-mediated diabetes mellitus.* Transplantation, 1996. 62(12): p. 1770-2.
5. Hadley, G.A., E.A. Rostapshova, and S.T. Bartlett, *Dominance of tissue-restricted cytotoxic T* *lymphocytes in the response to allogeneic renal epithelial cell lines.* Transplantation, 1996.62(1): p. 75-83.
6. Johnson, L.B., P.C. Kno, D.C. Dafoe, E.J. Schweitzer, E.J. Alfrey, D.K. Klassen, E.W. Hoehn-Saric, M.R. Weir, and S.T. Bartlett, *Double adult renal allografts: a technique for expansion of* *the cadaveric kidney donor pool.* Surgery, 1996. 120(4): p. 580-3; discussion 583-4.
7. Johnson, L.B., P.C. Kuo, D.C. Dafoe, C.B. Drachenberg, E.J. Schweitzer, E.J. Alfrey, L.A. Ridge, P. Salvatierra, J.C. Papadimitriou, W.J. Mergner, and S.T. Bartlett, *The use of bilateral* *adult renal allografts - a method to optimize function from donor kidneys with suboptimal nephron mass.* Transplantation, 1996. 61(8): p. 1261-3.
8. Johnson, L.B., P.C. Kuo, E.J. Schweitzer, L.E. Ratner, D.K. Klassen, E.W. Hoehn-Saric, A. dela Torre, M.R. Weir, J. Strange, and S.T. Bartlett, *Double renal allografts successfully increase* *utilization of kidneys from older donors within a single organ procurement organization.* Transplantation, 1996. 62(11): p. 1581-3.
9. Klassen, D.K., E.W. Hoen-Saric, M.R. Weir, J.C. Papadimitriou, C.B. Drachenberg, L. Johnson, E.J. Schweitzer, and S.T. Bartlett, *Isolated pancreas rejection in combined kidney pancreas* *tranplantation.* Transplantation, 1996. 61(6): p. 974-7.
10. Kuo, P.C., A. delaTorre, L.B. Johnson, E.J. Schweitzer, and S.T. Bartlett, *Bilateral* *retroperitoneal renal allografts: technique for placement through a midline incision.* J Am CollSurg, 1996. 183(5): p. 529-30.
11. Kuo, P.C., L.B. Johnson, G. Hastings, S.O. Pais, J.S. Plotkin, J.B. Orens, C.D. Howell, W.D. Lewis, and S.T. Bartlett, *Fulminant hepatic failure from the Budd-Chiari syndrome. A bridge to* *transplantation with transjugular intrahepatic portosystemic shunt.* Transplantation, 1996. 62(2):p. 294-6.
12. Kuo, P.C., L.B. Johnson, E.J. Schweitzer, E.J. Alfrey, J. Waskerwitz, and S.T. Bartlett, *Utilization of the older donor for renal transplantation.* Am J Surg, 1996. 172(5): p. 551-5;discussion 556-7.
13. Malinow, L., J. Walker, D. Klassen, D. Oldach, E. Schweitzer, S.T. Bartlett, and M.R. Weir, *Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.* ClinTransplant, 1996. 10(3): p. 237-42.

Stephen Thomas Bartlett, M.D.



Page 17

1. Papadimitriou, J., C. Drachenberg, L. Anderson, S. Bartlett, L. Johnson, D. Klassen, E. Hoehn-Saric, M. Weir, and E. Schweitzer, *Follow-up of patients with borderline changes in renal* *allograft biopsies: clinical outcome and evaluation of other histological features in addition to tubulitis.* Transplant Proc, 1996. 28(1): p. 517-8.
2. Schweitzer, E.J., C.B. Drachenberg, L. Anderson, J.C. Papadimetriou, P.C. Kuo, L.B. Johnson, D.K. Klassen, E. Hoehn-Saric, M.R. Weir, and S.T. Bartlett, *Significance of the Banff borderline* *biopsy.* Am J Kidney Dis, 1996. 28(4): p. 585-8.
3. Walker, J.A., D.K. Klassen, F.J. Hooper, E.W. Hoehn-Saric, E.J. Schweitzer, L.B. Johnson, S.T. Bartlett, and M.R. Weir, *Late pancreas allograft rejection. Preliminary experience with factors* *predisposing to rejection.* Transplantation, 1996. 62(4): p. 539-43.
4. Wong, J.J., T.L. Krebs, D.K. Klassen, B. Daly, E.M. Simon, S.T. Bartlett, K. Grumbach, and C.B. Drachenberg, *Sonographic evaluation of acute pancreatic transplant rejection:* *morphology-Doppler analysis versus guided percutaneous biopsy.* AJR Am J Roentgenol, 1996.166(4): p. 803-7.
5. Bartlett, S.T., E.J. Schweitzer, P.C. Kuo, L.B. Johnson, A. Delatorre, and G.A. Hadley, *Prevention of autoimmune islet allograft destruction by engraftment of donor T cells.* Transplantation, 1997. 63(2): p. 299-303.
6. delaTorre, A.N., P.C. Kuo, J.S. Plotkin, L.A. Ridge, C.D. Howell, S.T. Bartlett, and L.B. Johnson, *Influence of donor base deficit status on recipient outcomes in liver transplantation.* Transplant Proc, 1997. 29(1-2): p. 474.
7. Dorsey, S.G., C.F. Waltz, L. Brosch, I. Connerney, E.J. Schweitzer, and S.T. Bartlett, *A neural* *network model for predicting pancreas transplant graft outcome.* Diabetes Care, 1997. 20(7): p.1128-33.
8. Drachenberg, C.B., J.C. Papadimitriou, D.K. Klassen, L.C. Racusen, E.W. Hoehn-Saric, M.R. Weir, P.C. Kuo, E.J. Schweitzer, L.B. Johnson, and S.T. Bartlett, *Evaluation of pancreas* *transplant needle biopsy: reproducibility and revision of histologic grading system.* Transplantation, 1997. 63(11): p. 1579-86.
9. Drachenberg, C.B., E. Steinberger, E. Hoehn-Saric, A. Heffes, D.K. Klassen, S.T. Bartlett, and J.C. Papadimitriou, *Specificity of intertubular capillary changes: comparative ultrastructural* *studies in renal allografts and native kidneys.* Ultrastruct Pathol, 1997. 21(3): p. 227-33.
10. Flowers, J.L., S. Jacobs, E. Cho, A. Morton, W.F. Rosenberger, D. Evans, A.L. Imbembo, and S.T. Bartlett, *Comparison of open and laparoscopic live donor nephrectomy.* Ann Surg, 1997. 226(4): p. 483-9; discussion 489-90.
11. Hadley, G.A., S.T. Bartlett, C.S. Via, E.A. Rostapshova, and S. Moainie, *The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL.* JImmunol, 1997. 159(8): p. 3748-56.
12. Johnson, L.B., J.S. Plotkin, C.D. Howell, M.J. Njoku, P.C. Kuo, and S.T. Bartlett, *Successful* *emergency transplantation of a liver allograft from a donor maintained on extracorporeal membrane oxygenation.* Transplantation, 1997. 63(6): p. 910-1.
13. Kuo, P.C., S.T. Bartlett, J.W. Lim, J.S. Plotkin, S. Wilson, and L.B. Johnson, *Selective bowel* *decontamination in hospitalized patients awaiting liver transplantation.* Am J Surg, 1997.174(6): p. 745-8; discussion 749.
14. Kuo, P.C., S.T. Bartlett, E.J. Schweitzer, L.B. Johnson, J.W. Lim, and D.C. Dafoe, *A technique* *for management of multiple renal arteries after laparoscopic donor nephrectomy.* Transplantation, 1997. 64(5): p. 779-80.

Stephen Thomas Bartlett, M.D.



Page 18

1. Kuo, P.C., L.B. Johnson, J.S. Plotkin, C.D. Howell, S.T. Bartlett, and L.J. Rubin, *Continuous* *intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.* Transplantation, 1997. 63(4): p. 604-6.
2. Kuo, P.C., L.B. Johnson, E.J. Schweitzer, and S.T. Bartlett, *Simultaneous pancreas/kidney* *transplantation--a comparison of enteric and bladder drainage of exocrine pancreatic secretions.* Transplantation, 1997. 63(2): p. 238-43.
3. Kuo, P.C., L.B. Johnson, E.J. Schweitzer, D.K. Klassen, E.W. Hoehn-Saric, M.R. Weir, C.B. Drachenberg, J.C. Papadimitriou, and S.T. Bartlett, *Solitary pancreas allografts. The role of* *percutaneous biopsy and standardized histologic grading of rejection.* Arch Surg, 1997. 132(1):p. 52-7.
4. Kuo, P.C., J.S. Plotkin, L.B. Johnson, C.D. Howell, J.M. Laurin, S.T. Bartlett, and L.J. Rubin, *Distinctive clinical features of portopulmonary hypertension.* Chest, 1997. 112(4): p. 980-6.
5. Kuo, P.C., R.A. Schroeder, and S.T. Bartlett, *Endotoxin-mediated synthesis of nitric oxide is* *dependent on Gq protein signal transduction.* Surgery, 1997. 122(2): p. 394-402; discussion 402-3.
6. Kuo, P.C., J. Wong, E.J. Schweitzer, L.B. Johnson, J.W. Lim, and S.T. Bartlett, *Outcome after* *splenic vein thrombosis in the pancreas allograft.* Transplantation, 1997. 64(6): p. 933-5.
7. Madayag, R.M., L.B. Johnson, S.T. Bartlett, E.J. Schweitzer, N.T. Constantine, R.J. McCarter, Jr., P.C. Kuo, S. Keay, and D.W. Oldach, *Use of renal allografts from donors positive for* *hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease.* Transplantation, 1997. 64(12): p. 1781-6.
8. Papadimitriou, J.C., C.B. Drachenberg, G.A. Hadley, S.T. Bartlett, and B.F. Trump, *Interaction* *between cytolytic T-cells and immobilized renal tubular epithelial cells: evidence of polarity on both effector and target cells.* J Submicrosc Cytol Pathol, 1997. 29(3): p. 379-86.
9. Papadimitriou, J.C., D.K. Klassen, O.B. Ioffe, S.T. Bartlett, J.R. Hebel, and C.B. Drachenberg, *Identification of histological features differentiating pancreatic allograft rejection from nonrejection-related pathology in needle biopsies.* Transplant Proc, 1997. 29(1-2): p. 679.
10. Plotkin, J.S., J.F. Buell, M.J. Njoku, S. Wilson, P.C. Kuo, S.T. Bartlett, C. Howell, and L.B. Johnson, *Methemoglobinemia associated with dapsone treatment in solid organ transplant* *recipients: a two-case report and review.* Liver Transpl Surg, 1997. 3(2): p. 149-52.
11. Plotkin, J.S., M. Njoku, C.D. Howell, P.C. Kuo, J.W. Lim, J.M. Laurin, S.T. Bartlett, and L.B. Johnson, *The evolution of a successful liver transplant program in 1996: the clinical and* *administrative role of the anesthesiologist.* Liver Transpl Surg, 1997. 3(4): p. 468-70.
12. Schweitzer, E.J., L. Anderson, P.C. Kuo, L.B. Johnson, D.K. Klassen, E. Hoehn-Saric, M.R. Weir, and S.T. Bartlett, *Safe pancreas transplantation in patients with coronary artery disease.* Transplantation, 1997. 63(9): p. 1294-9.
13. Schweitzer, E.J., S. Yoon, J. Hart, L. Anderson, R. Barnes, D. Evans, K. Hartman, J. Jaekels, L.B. Johnson, P.C. Kuo, E. Hoehn-Saric, D.K. Klassen, M.R. Weir, and S.T. Bartlett, *Increased* *living donor volunteer rates with a formal recipient family education program.* Am J KidneyDis, 1997. 29(5): p. 739-45.
14. Weir, M.R., L. Anderson, J.C. Fink, K. Gabregiorgish, E.J. Schweitzer, E. Hoehn-Saric, D.K. Klassen, C.B. Cangro, L.B. Johnson, P.C. Kuo, J.Y. Lim, and S.T. Bartlett, *A novel approach to* *the treatment of chronic allograft nephropathy.* Transplantation, 1997. 64(12): p. 1706-10.
15. Zachary, A.A., J.M. Hart, S.T. Bartlett, J. Burdick, P. Colombani, L.E. Ratner, and M.S. Leffell, *Local impact of 1995 changes in the renal transplant allocation system.* Transplantation, 1997.63(5): p. 669-74.

Stephen Thomas Bartlett, M.D.



Page 19

1. Bartlett, S.T., A.C. Farney, B.E. Jarrell, B. Philosophe, J.O. Colonna, A. Wiland, S. Keay, and E.J. Schweitzer, *Kidney transplantation at the University of Maryland.* Clin Transpl, 1998: p. 177-85.
2. Del Pizzo, J.J., S.C. Jacobs, S.T. Bartlett, and G.N. Sklar, *Urological complications of bladder-drained pancreatic allografts.* Br J Urol, 1998. 81(4): p. 543-7.
3. del Pizzo, J.J., S.C. Jacobs, S.T. Bartlett, and G.N. Sklar, *The use of bladder for total transplant* *ureteral reconstruction.* J Urol, 1998. 159(3): p. 750-2; discussion 752-3.
4. delaTorre, A., R.A. Schroeder, S.T. Bartlett, and P.C. Kuo, *Differential effects of nitric oxide-mediated S-nitrosylation on p50 and c-jun DNA binding.* Surgery, 1998. 124(2): p. 137-41;discussion 141-2.
5. Drachenberg, C.B., L.V. Abruzzo, D.K. Klassen, S.T. Bartlett, L.B. Johnson, P.C. Kuo, D. Kumar, and J.C. Papadimitriou, *Epstein-Barr virus-related posttransplantation* *lymphoproliferative disorder involving pancreas allografts: histological differential diagnosis from acute allograft rejection.* Hum Pathol, 1998. 29(6): p. 569-77.
6. Drachenberg, C.B., J.C. Papadimitriou, D.K. Klassen, M.R. Weir, and S.T. Bartlett, *Distribution* *of alpha and beta cells in pancreas allograft biopsies: correlation with rejection and other pathologic processes.* Transplant Proc, 1998. 30(2): p. 665-6.
7. Gruessner, R.W., S.T. Bartlett, G.W. Burke, and P.G. Stock, *Suggested guidelines for the use of* *tacrolimus in pancreas/kidney transplantation.* Clin Transplant, 1998. 12(3): p. 260-2.
8. Keay, S., D. Oldach, A. Wiland, D. Klassen, E. Schweitzer, L.V. Abruzzo, D. Kumar, and S. Bartlett, *Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased* *antiviral prophylaxis in pancreas transplant recipients.* Clin Infect Dis, 1998. 26(3): p. 596-600.
9. Kuo, P.C., E.S. Cho, J.L. Flowers, S. Jacobs, S.T. Bartlett, and L.B. Johnson, *Laparoscopic* *living donor nephrectomy and multiple renal arteries.* Am J Surg, 1998. 176(6): p. 559-63.
10. Kuo, P.C., C.I. Drachenberg, A. de la Torre, S.T. Bartlett, J.W. Lim, J.S. Plotkin, and L.B. Johnson, *Apoptosis and hepatic allograft reperfusion injury.* Clin Transplant, 1998. 12(3): p.

219-23.

1. Papadimitriou, J.C., C.B. Drachenberg, D.K. Klassen, M.R. Weir, and S.T. Bartlett, *Histologic* *grading scheme for pancreas allograft rejection: application in the differential diagnosis from other pathologic entities.* Transplant Proc, 1998. 30(2): p. 267.
2. Papadimitriou, J.C., C.B. Drachenberg, A. Wiland, D.K. Klassen, J. Fink, M.R. Weir, C. Cangro, E.J. Schweitzer, and S.T. Bartlett, *Histologic grading of acute allograft rejection in pancreas* *needle biopsy: correlation to serum enzymes, glycemia, and response to immunosuppressive treatment.* Transplantation, 1998. 66(12): p. 1741-5.
3. Papadimitriou, J.C., J. Nogueira, J.C. Fink, D.K. Klassen, S.T. Bartlett, M.R. Weir, and C.B. Drachenberg, *Importance of degree of eosinophilia in inflammatory infiltrates within renal* *allografts in the response to immunosuppressive treatment.* Transplant Proc, 1998. 30(4): p.1181.
4. Papadimitriou, J.C., A. Wiland, C.B. Drachenberg, D.K. Klassen, and S.T. Bartlett, *Effectiveness* *of immunosuppressive treatment for recurrent or refractory pancreas allograft rejection: correlation with histologic grade.* Transplant Proc, 1998. 30(8): p. 3945.
5. Rostapshova, E.A., J.M. Burns, S.T. Bartlett, and G.A. Hadley, *Integrin-mediated interactions* *influence the tissue specificity of CD8+ cytolytic T lymphocytes.* Eur J Immunol, 1998. 28(10): p.3031-9.
6. Schweitzer, E.J., A. Wiland, D. Evans, M. Novak, I. Connerny, L. Norris, J.O. Colonna, B. Philosophe, A.C. Farney, B.E. Jarrell, and S.T. Bartlett, *The shrinking renal replacement therapy* *"break-even" point.* Transplantation, 1998. 66(12): p. 1702-8.

Stephen Thomas Bartlett, M.D.



Page 20

1. Schweitzer, E.J., S. Yoon, J. Fink, A. Wiland, L. Anderson, P.C. Kuo, J.W. Lim, L.B. Johnson, A.C. Farney, M.R. Weir, and S.T. Bartlett, *Mycophenolate mofetil reduces the risk of acute* *rejection less in African-American than in Caucasian kidney recipients.* Transplantation, 1998.65(2): p. 242-8.
2. Wong-You-Cheong, J.J., K. Grumbach, T.L. Krebs, M.E. Pace, B. Daly, C.C. Chow, L.B. Johnson, and S.T. Bartlett, *Torsion of intraperitoneal renal transplants: imaging appearances.* AJR Am J Roentgenol, 1998. 171(5): p. 1355-9.
3. Allen, E.M. and S.T. Bartlett, *The effect of methimazole, iodine and splenocytes on thyroid* *transplants in BB/Wor rats.* Transplantation, 1999. 68(1): p. 25-30.
4. Drachenberg, C.B., C.O. Beskow, C.B. Cangro, P.M. Bourquin, A. Simsir, J. Fink, M.R. Weir, D.K. Klassen, S.T. Bartlett, and J.C. Papadimitriou, *Human polyoma virus in renal allograft* *biopsies: morphological findings and correlation with urine cytology.* Hum Pathol, 1999. 30(8):p. 970-7.
5. Drachenberg, C.B., D.K. Klassen, M.R. Weir, A. Wiland, J.C. Fink, S.T. Bartlett, C.B. Cangro, S. Blahut, and J.C. Papadimitriou, *Islet cell damage associated with tacrolimus and* *cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation.* Transplantation, 1999. 68(3): p. 396-402.
6. Drachenberg, C.B., J.C. Papadimitriou, D.K. Klassen, M.R. Weir, C.B. Cangro, J.C. Fink, and S.T. Bartlett, *Chronic pancreas allograft rejection: morphologic evidence of progression in* *needle biopsies and proposal of a grading scheme.* Transplant Proc, 1999. 31(1-2): p. 614.
7. Hadley, G.A., E.A. Rostapshova, D.M. Gomolka, B.M. Taylor, S.T. Bartlett, C.I. Drachenberg, and M.R. Weir, *Regulation of the epithelial cell-specific integrin, CD103, by human CD8+* *cytolytic T lymphocytes.* Transplantation, 1999. 67(11): p. 1418-25.
8. Krebs, T.L., B. Daly, J.J. Wong-You-Cheong, K. Carroll, and S.T. Bartlett, *Acute pancreatic* *transplant rejection: evaluation with dynamic contrast-enhanced MR imaging compared with histopathologic analysis.* Radiology, 1999. 210(2): p. 437-42.
9. Nogueira, J.M., C.B. Cangro, J.C. Fink, E. Schweitzer, A. Wiland, D.K. Klassen, J. Gardner, J. Flowers, S. Jacobs, E. Cho, B. Philosophe, S.T. Bartlett, and M.R. Weir, *A comparison of* *recipient renal outcomes with laparoscopic versus open live donor nephrectomy.* Transplantation, 1999. 67(5): p. 722-8.
10. Passalacqua, J.A., A.M. Wiland, J.C. Fink, S.T. Bartlett, D.A. Evans, and S. Keay, *Increased* *incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients.* Transplantation, 1999. 68(4): p. 535-40.
11. Pfundstein, J., M.C. Roghmann, R.S. Schwalbe, S.Q. Qaiyumi, R.J. McCarter, Jr., S. Keay, E. Schweitzer, S.T. Bartlett, J.G. Morris, Jr., and D.W. Oldach, *A randomized trial of surgical* *antimicrobial prophylaxis with and without vancomycin in organ transplant patients.* ClinTransplant, 1999. 13(3): p. 245-52.
12. Philosophe, B., P.C. Kuo, E.J. Schweitzer, A.C. Farney, J.W. Lim, L.B. Johnson, S. Jacobs, J.L. Flowers, E.S. Cho, and S.T. Bartlett, *Laparoscopic versus open donor nephrectomy: comparing* *ureteral complications in the recipients and improving the laparoscopic technique.*

Transplantation, 1999. 68(4): p. 497-502.

1. Weir, M.R., J.C. Fink, D.S. Hanes, J. Gardner, D.K. Klassen, C. Cangro, E. Schweitzer, and S.T. Bartlett, *Chronic allograft nephropathy: effect of cyclosporine reduction and addition of* *mycophenolate mofetil on progression of renal disease.* Transplant Proc, 1999. 31(1-2): p. 1286-7.
2. Bartlett, S.T., D. Oldach, and S.C. Schimpff, *Organs for transplantation.* N Engl J Med, 2000. 343(23): p. 1731; author reply 1732.

Stephen Thomas Bartlett, M.D.



Page 21

1. Farney, A.C., E. Cho, E.J. Schweitzer, B. Dunkin, B. Philosophe, J. Colonna, S. Jacobs, B. Jarrell, J.L. Flowers, and S.T. Bartlett, *Simultaneous cadaver pancreas living-donor kidney* *transplantation: a new approach for the type 1 diabetic uremic patient.* Ann Surg, 2000. 232(5):p. 696-703.
2. Glassman, D.T., L. Nipkow, S.T. Bartlett, and S.C. Jacobs, *Bilateral nephrectomy with* *concomitant renal graft transplantation for autosomal dominant polycystic kidney disease.* JUrol, 2000. 164(3 Pt 1): p. 661-4.
3. Jacobs, S.C., E. Cho, B.J. Dunkin, S.T. Bartlett, J.L. Flowers, B. Jarrell, and S.C. Jacobs, *Laparoscopic nephrectomy in the markedly obese living renal donor.* Urology, 2000. 56(6): p.926-9.
4. Jacobs, S.C., E. Cho, B.J. Dunkin, J.L. Flowers, E. Schweitzer, C. Cangro, J. Fink, A. Farney, B. Philosophe, B. Jarrell, and S.T. Bartlett, *Laparoscopic live donor nephrectomy: the University of* *Maryland 3-year experience.* J Urol, 2000. 164(5): p. 1494-9.
5. Klassen, D.K., C.B. Drachenberg, J.C. Papadimitriou, C.B. Cangro, J.C. Fink, S.T. Bartlett, and M.R. Weir, *CMV allograft pancreatitis: diagnosis, treatment, and histological features.* Transplantation, 2000. 69(9): p. 1968-71.
6. Meador, T.L., T.L. Krebs, J.J. Cheong, B. Daly, S. Keay, and S. Bartlett, *Imaging features of* *posttransplantation lymphoproliferative disorder in pancreas transplant recipients.* AJR Am JRoentgenol, 2000. 174(1): p. 121-4.
7. Philosophe, B., A.C. Farney, E.J. Schweitzer, J.O. Colonna, B.E. Jarrell, C.E. Foster, 3rd, A.M. Wiland, and S.T. Bartlett, *Simultaneous pancreas-kidney (SPK) and pancreas living-donor* *kidney (SPLK) transplantation at the University of Maryland.* Clin Transpl, 2000: p. 211-6.
8. Schweitzer, E.J., J. Wilson, S. Jacobs, C.H. Machan, B. Philosophe, A. Farney, J. Colonna, B.E. Jarrell, and S.T. Bartlett, *Increased rates of donation with laparoscopic donor nephrectomy.* Ann Surg, 2000. 232(3): p. 392-400.
9. Schweitzer, E.J., J.S. Wilson, M. Fernandez-Vina, M. Fox, M. Gutierrez, A. Wiland, J. Hunter, A. Farney, B. Philosophe, J. Colonna, B.E. Jarrell, and S.T. Bartlett, *A high panel-reactive* *antibody rescue protocol for cross-match-positive live donor kidney transplants.* Transplantation,2000. 70(10): p. 1531-6.
10. Stephens, J.K., G.T. Everson, C.L. Elliott, I. Kam, M. Wachs, J. Haney, S.T. Bartlett, and W.A. Franklin, *Fatal transfer of malignant melanoma from multiorgan donor to four allograft* *recipients.* Transplantation, 2000. 70(1): p. 232-6.
11. Buell, J.F., M. Edye, M. Johnson, C. Li, A. Koffron, E. Cho, P. Kuo, L. Johnson, M. Hanaway, S.R. Potter, D.S. Bruce, D.C. Cronin, K.A. Newell, J. Leventhal, S. Jacobs, E.S. Woodle, S.T. Bartlett, and J.L. Flowers, *Are concerns over right laparoscopic donor nephrectomy* *unwarranted?* Ann Surg, 2001. 233(5): p. 645-51.
12. Drachenberg, C.B., J.C. Papadimitriou, A. Farney, A. Wiland, S. Blahut, J.C. Fink, B. Philosophe, E. Schweitzer, T. Lal, L. Anderson, and S.T. Bartlett, *Pancreas transplantation: the* *histologic morphology of graft loss and clinical correlations.* Transplantation, 2001. 71(12): p.1784-91.
13. Drachenberg, R.C., C.B. Drachenberg, J.C. Papadimitriou, E. Ramos, J.C. Fink, R. Wali, M.R. Weir, C.B. Cangro, D.K. Klassen, A. Khaled, R. Cunningham, and S.T. Bartlett, *Morphological* *spectrum of polyoma virus disease in renal allografts: diagnostic accuracy of urine cytology.* Am J Transplant, 2001. 1(4): p. 373-81.
14. Hadley, G.A., C. Charandee, M.R. Weir, D. Wang, S.T. Bartlett, and C.B. Drachenberg, *CD103+* *CTL accumulate within the graft epithelium during clinical renal allograft rejection.* Transplantation, 2001. 72(9): p. 1548-55.

Stephen Thomas Bartlett, M.D.



Page 22

1. Krishnamurthi, V., B. Philosophe, and S.T. Bartlett, *Pancreas transplantation: contemporary*

*surgical techniques.* Urol Clin North Am, 2001. 28(4): p. 833-8.

1. Oh, J.M., A.M. Wiland, D.K. Klassen, P.J. Weidle, and S.T. Bartlett, *Comparison of* *azathioprine and mycophenolate mofetil for the prevention of acute rejection in recipients of pancreas transplantation.* J Clin Pharmacol, 2001. 41(8): p. 861-9.
2. Okitsu, T., S.T. Bartlett, G.A. Hadley, C.B. Drachenberg, and A.C. Farney, *Recurrent* *autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice.* Am J Transplant, 2001. 1(2): p. 138-45.
3. Papadimitriou, J.C., C.B. Drachenberg, C.O. Beskow, C. Cangro, A. Wiland, D. Klassen, M. Weir, and S. Bartlett, *Graft-versus-host disease-like features in mycophenolate mofetil-related* *colitis.* Transplant Proc, 2001. 33(3): p. 2237-8.
4. Philosophe, B., A.C. Farney, E.J. Schweitzer, J.O. Colonna, B.E. Jarrell, V. Krishnamurthi, A.M. Wiland, and S.T. Bartlett, *Superiority of portal venous drainage over systemic venous drainage* *in pancreas transplantation: a retrospective study.* Ann Surg, 2001. 234(5): p. 689-96.
5. Weir, M.R., M.T. Ward, S.A. Blahut, D.K. Klassen, C.B. Cangro, S.T. Bartlett, and J.C. Fink, *Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.* Kidney Int, 2001. 59(4): p. 1567-73.
6. Wiland, A.M., J.C. Fink, B. Philosophe, A.C. Farney, E.J. Schweitzer, J.O. Colonna, M.R. Weir, and S.T. Bartlett, *Peripheral administration of thymoglobulin for induction therapy in pancreas* *transplantation.* Transplant Proc, 2001. 33(1-2): p. 1910.
7. Adams, P.L., D.J. Cohen, G.M. Danovitch, R.M. Edington, R.S. Gaston, C.L. Jacobs, R.S. Luskin, R.A. Metzger, T.G. Peters, L.A. Siminoff, R.M. Veatch, L. Rothberg-Wegman, S.T. Bartlett, L. Brigham, J. Burdick, S. Gunderson, W. Harmon, A.J. Matas, J.R. Thistlethwaite, and F.L. Delmonico, *The nondirected live-kidney donor: ethical considerations and practice* *guidelines: A National Conference Report.* Transplantation, 2002. 74(4): p. 582-9.
8. Arnold, R., S. Bartlett, J. Bernat, J. Colonna, D. Dafoe, N. Dubler, S. Gruber, J. Kahn, R. Luskin,
   1. Nathan, S. Orloff, J. Prottas, R. Shapiro, C. Ricordi, S. Youngner, and F.L. Delmonico, *Financial incentives for cadaver organ donation: an ethical reappraisal.* Transplantation, 2002.73(8): p. 1361-7.
9. Bartlett, S.T., *Laparoscopic donor nephrectomy after seven years.* Am J Transplant, 2002. 2(10): p. 896-7.
10. Fink, J.C., M.A. Onuigbo, S.A. Blahut, R.H. Christenson, D. Mann, S.T. Bartlett, and M.R. Weir, *Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study.* Am J Kidney Dis, 2002. 39(5): p. 1096-101.
11. Foster, C.E., 3rd, B. Philosophe, E.J. Schweitzer, J.O. Colonna, A.C. Farney, B. Jarrell, L. Anderson, and S.T. Bartlett, *A decade of experience with renal transplantation in African-Americans.* Ann Surg, 2002. 236(6): p. 794-804; discussion 804-805.
12. Hankey, K.G., C.B. Drachenberg, J.C. Papadimitriou, D.K. Klassen, B. Philosophe, S.T. Bartlett,
    1. Groh, T. Spies, and D.L. Mann, *MIC expression in renal and pancreatic allografts.* Transplantation, 2002. 73(2): p. 304-6.
13. Klassen, D.K., M.R. Weir, C.B. Cangro, S.T. Bartlett, J.C. Papadimitriou, and C.B. Drachenberg, *Pancreas allograft biopsy: safety of percutaneous biopsy-results of a large experience.* Transplantation, 2002. 73(4): p. 553-5.
14. Ramos, E., C.B. Drachenberg, J.C. Papadimitriou, O. Hamze, J.C. Fink, D.K. Klassen, R.C. Drachenberg, A. Wiland, R. Wali, C.B. Cangro, E. Schweitzer, S.T. Bartlett, and M.R. Weir, *Clinical course of polyoma virus nephropathy in 67 renal transplant patients.* J Am Soc Nephrol,2002. 13(8): p. 2145-51.

Stephen Thomas Bartlett, M.D.



Page 23

1. Ramos, E., C.B. Drachenberg, M. Portocarrero, R. Wali, D.K. Klassen, J.C. Fink, A. Farney, H. Hirsch, J.C. Papadimitriou, C.B. Cangro, M.R. Weir, and S.T. Bartlett, *BK virus nephropathy* *diagnosis and treatment: experience at the University of Maryland Renal Transplant Program.* Clin Transpl, 2002: p. 143-53.
2. Matas, A.J., S.T. Bartlett, A.B. Leichtman, and F.L. Delmonico, *Morbidity and mortality after* *living kidney donation, 1999-2001: survey of United States transplant centers.* Am J Transplant,2003. 3(7): p. 830-4.
3. Mullins, C.D., S.K. Thomas, F.G. Pradel, and S.T. Bartlett, *The economic impact of laparoscopic* *living-donor nephrectomy on kidney transplantation.* Transplantation, 2003. 75(9): p. 1505-12.
4. Papadimitriou, J.C., C.B. Drachenberg, D.K. Klassen, L. Gaber, L.C. Racusen, L. Voska, C.B. Cangro, E. Ramos, R. Wali, M.R. Weir, and S.T. Bartlett, *Histological grading of chronic* *pancreas allograft rejection/graft sclerosis.* Am J Transplant, 2003. 3(5): p. 599-605.
5. Pradel, F.G., M.R. Limcangco, C.D. Mullins, and S.T. Bartlett, *Patients' attitudes about living* *donor transplantation and living donor nephrectomy.* Am J Kidney Dis, 2003. 41(4): p. 849-58.
6. Pradel, F.G., C.D. Mullins, and S.T. Bartlett, *Exploring donors' and recipients' attitudes about* *living donor kidney transplantation.* Prog Transplant, 2003. 13(3): p. 203-10.
7. Borboroglu, P.G., C.E. Foster, 3rd, B. Philosophe, A.C. Farney, J.O. Colonna, E.J. Schweitzer, and S.T. Bartlett, *Solitary renal allografts from pediatric cadaver donors less than 2 years of age* *transplanted into adult recipients.* Transplantation, 2004. 77(5): p. 698-702.
8. Drachenberg, C.B., J.C. Papadimitriou, E. Schweitzer, B. Philosophe, C. Foster, and S.T. Bartlett, *Histological findings in "incidental" intraoperative pancreas allograft biopsies.* Transplant Proc, 2004. 36(3): p. 780-1.
9. Drachenberg, C.B., J.C. Papadimitriou, R. Wali, J. Nogueira, S. Mendley, H.H. Hirsch, C.B. Cangro, D.K. Klassen, M.R. Weir, S.T. Bartlett, and E. Ramos, *Improved outcome of polyoma* *virus allograft nephropathy with early biopsy.* Transplant Proc, 2004. 36(3): p. 758-9.
10. Jacobs, S.C., E. Cho, C. Foster, P. Liao, and S.T. Bartlett, *Laparoscopic donor nephrectomy: the*

*University of Maryland 6-year experience.* J Urol, 2004. 171(1): p. 47-51.

1. Jacobs, S.C., J.R. Ramey, G.N. Sklar, and S.T. Bartlett, *Laparoscopic kidney donation from* *patients older than 60 years.* J Am Coll Surg, 2004. 198(6): p. 892-7.
2. Leeser, D.B. and S.T. Bartlett, *Evolving surgical strategies for pancreas transplantation.* Curr Diab Rep, 2004. 4(4): p. 310-5.
3. Leeser, D.B., A.W. Bingaman, L. Poliakova, Q. Shi, F. Gage, S.T. Bartlett, and A.C. Farney, *Pulsatile pump perfusion of pancreata before human islet cell isolation.* Transplant Proc, 2004.36(4): p. 1050-1.
4. Papadimitriou, J.C., R. Coale, A. Farney, E. Schweitzer, C. Foster, L. Campos, and S. Bartlett, *Biopsy of the marginal kidney donor: correlation of histology with outcome.* Transplant Proc,2004. 36(3): p. 742-4.
5. Shi, Q., D. Wang, G.A. Hadley, A.W. Bingaman, S.T. Bartlett, and D.L. Farber, *Long-term islet* *graft survival in NOD mice by abrogation of recurrent autoimmunity.* Diabetes, 2004. 53(9): p.2338-45.
6. Wali, R.K., C. Drachenberg, H.H. Hirsch, J. Papadimitriou, A. Nahar, V. Mohanlal, M.A. Brisco, S.T. Bartlett, M.R. Weir, and E. Ramos, *BK virus-associated nephropathy in renal allograft* *recipients: rescue therapy by sirolimus-based immunosuppression.* Transplantation, 2004. 78(7):p. 1069-73.
7. Weir, M.R., S. Blahut, C. Drachenburg, C. Young, J. Papademitriou, D.K. Klassen, C.B. Cangro, S.T. Bartlett, and J.C. Fink, *Late calcineurin inhibitor withdrawal as a strategy to prevent graft*

Stephen Thomas Bartlett, M.D.



Page 24

*loss in patients with suboptimal kidney transplant function.* Am J Nephrol, 2004. 24(4): p. 379-86.

1. Wiland, A.M., J.C. Fink, M.R. Weir, B. Philosophe, S. Blahut, M.R. Weir, Jr., B. Copenhaver, and S.T. Bartlett, *Should living-unrelated renal transplant recipients receive antibody induction?* *Results of a clinical experience trial.* Transplantation, 2004. 77(3): p. 422-5.
2. Bingaman, A.W., D.S. Patke, V.R. Mane, M. Ahmadzadeh, M. Ndejembi, S.T. Bartlett, and D.L. Farber, *Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in* *lymphoid and lung tissue.* Eur J Immunol, 2005. 35(11): p. 3173-86.
3. Foster, C.E., 3rd, P.G. Borboroglu, S.T. Bartlett, and S. Jacobs, *Nonelective laparoscopic donor* *nephrectomy can be done safely.* Curr Surg, 2005. 62(1): p. 103-5.
4. Wali, R.K., G.S. Wang, S.S. Gottlieb, L. Bellumkonda, R. Hansalia, E. Ramos, C. Drachenberg,
   1. Papadimitriou, M.A. Brisco, S. Blahut, J.C. Fink, M.L. Fisher, S.T. Bartlett, and M.R. Weir, *Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease.* J Am Coll Cardiol, 2005. 45(7): p. 1051-60.
5. Shi, Q., D. Wang, G.A. Hadley, D.L. Farber, and S.T. Bartlett, *Abrogation of recurrent* *autoimmunity in the NOD mouse: A critical role for host interleukin 4.* Surgery, 2006. 140(2): p.281-8.
6. Buadi, F.K., M.R. Heyman, C.D. Gocke, A.P. Rapoport, R. Hakimian, S.T. Bartlett, and C. Sarkodee-Adoo, *Treatment and outcomes of post-transplant lymphoproliferative disease: a* *single institution study.* Am J Hematol, 2007. 82(3): p. 208-14.
7. Neschis, D.G., R. Gutta, H.S. Al-Qudah, S.T. Bartlett, B. Philosophe, E.J. Schweitzer, W.R. Flinn, and L. Campos, *Intraoperative coil embolization reduces transplant nephrectomy* *transfusion requirement.* Vasc Endovascular Surg, 2007. 41(4): p. 335-8.
8. Pradel, F.G. and S.T. Bartlett, *Does a home-based education program improve rates of living* *donor kidney transplantation?* Nat Clin Pract Nephrol, 2007. 3(7): p. 366-7.
9. Schweitzer, E.J., E.N. Perencevich, B. Philosophe, and S.T. Bartlett, *Estimated benefits of* *transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection.* Am JTransplant, 2007. 7(6): p. 1515-25.
10. Wali, R.K., V. Mohanlal, E. Ramos, S. Blahut, C. Drachenberg, J. Papadimitriou, M. Dinits, A. Joshi, B. Philosophe, C. Foster, C. Cangro, J. Nogueira, M. Cooper, S.T. Bartlett, and M.R. Weir, *Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.* Am JTransplant, 2007. 7(6): p. 1572-83.
11. Abecassis, M., S.T. Bartlett, A.J. Collins, C.L. Davis, F.L. Delmonico, J.J. Friedewald, R. Hays,
    1. Howard, E. Jones, A.B. Leichtman, R.M. Merion, R.A. Metzger, F. Pradel, E.J. Schweitzer, R.L. Velez, and R.S. Gaston, *Kidney transplantation as primary therapy for end-stage renal* *disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference.* Clin J Am Soc Nephrol, 2008. 3(2): p. 471-80.
12. Drachenberg, C.B., J. Odorico, A.J. Demetris, L. Arend, I.M. Bajema, J.A. Bruijn, D. Cantarovich, H.P. Cathro, J. Chapman, K. Dimosthenous, B. Fyfe-Kirschner, L. Gaber, O. Gaber,
    1. Goldberg, E. Honsova, S.S. Iskandar, D.K. Klassen, B. Nankivell, J.C. Papadimitriou, L.C. Racusen, P. Randhawa, F.P. Reinholt, K. Renaudin, P.P. Revelo, P. Ruiz, J.R. Torrealba, E. Vazquez-Martul, L. Voska, R. Stratta, S.T. Bartlett, and D.E. Sutherland, *Banff schema for* *grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel.* Am J Transplant, 2008. 8(6): p. 1237-49.

Stephen Thomas Bartlett, M.D.



Page 25

1. Gallagher, K.A., M.W. Phelan, T. Stern, and S.T. Bartlett, *Repair of complex renal artery* *aneurysms by laparoscopic nephrectomy with ex vivo repair and autotransplantation.* J VascSurg, 2008. 48(6): p. 1408-13.
2. Hitti, W.A., J.C. Papadimitriou, S. Bartlett, and R.K. Wali, *Spontaneous cutaneous ulcers in a* *patient with a moderate degree of chronic kidney disease: a different spectrum of calciphylaxis.* Scand J Urol Nephrol, 2008. 42(2): p. 181-3.
3. Jacobs, S.C., J.M. Nogueira, M.W. Phelan, S.T. Bartlett, and M. Cooper, *Transplant recipient* *renal function is donor renal mass- and recipient gender-dependent.* Transpl Int, 2008. 21(4): p.340-5.
4. Munivenkatappa, R.B., E.J. Schweitzer, J.C. Papadimitriou, C.B. Drachenberg, K.A. Thom, E.N. Perencevich, A. Haririan, F. Rasetto, M. Cooper, L. Campos, R.N. Barth, S.T. Bartlett, and B. Philosophe, *The Maryland aggregate pathology index: a deceased donor kidney biopsy scoring* *system for predicting graft failure.* Am J Transplant, 2008. 8(11): p. 2316-24.
5. Poston, R.S., R. Tran, M. Collins, M. Reynolds, I. Connerney, B. Reicher, D. Zimrin, B.P. Griffith, and S.T. Bartlett, *Comparison of economic and patient outcomes with minimally* *invasive versus traditional off-pump coronary artery bypass grafting techniques.* Ann Surg,2008. 248(4): p. 638-46.
6. Pradel, F.G., R. Jain, C.D. Mullins, J.A. Vassalotti, and S.T. Bartlett, *A survey of nephrologists'* *views on preemptive transplantation.* Clin J Am Soc Nephrol, 2008. 3(6): p. 1837-45.
7. Pradel, F.G., P. Suwannaprom, C.D. Mullins, J. Sadler, and S.T. Bartlett, *Short-term impact of an* *educational program promoting live donor kidney transplantation in dialysis centers.* ProgTransplant, 2008. 18(4): p. 263-72.
8. Roland, M.E., B. Barin, L. Carlson, L.A. Frassetto, N.A. Terrault, R. Hirose, C.E. Freise, L.Z. Benet, N.L. Ascher, J.P. Roberts, B. Murphy, M.J. Keller, K.M. Olthoff, E.A. Blumberg, K.L. Brayman, S.T. Bartlett, C.E. Davis, J.M. McCune, B.M. Bredt, D.M. Stablein, and P.G. Stock, *HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes.* Am J Transplant,2008. 8(2): p. 355-65.
9. Scalea, J.R., C.C. Butler, R.B. Munivenkatappa, J.M. Nogueira, L. Campos, A. Haririan, R.N. Barth, B. Philosophe, S.T. Bartlett, and M. Cooper, *Pancreas transplant alone as an independent* *risk factor for the development of renal failure: a retrospective study.* Transplantation, 2008.86(12): p. 1789-94.
10. Silverman, R.P., N.D. Banks, L.J. Detolla, S.T. Shipley, A. Panda, R.A. Sanchez, A.M. Azimzadeh, R.N. Pierson, 3rd, D. Wang, E.D. Rodriguez, L.H. Holton, 3rd, and S.T. Bartlett, *A* *heterotopic primate model for facial composite tissue transplantation.* Ann Plast Surg, 2008.60(2): p. 209-16.
11. Barth, R.N., R. Bluebond-Langner, A. Nam, M. Stanwix, S. Shipley, S.T. Bartlett, and E.D. Rodriguez, *Facial subunit composite tissue allografts in nonhuman primates: I. Technical and* *immunosuppressive requirements for prolonged graft survival.* Plast Reconstr Surg, 2009.123(2): p. 493-501.
12. Barth, R.N., A.J. Nam, M.G. Stanwix, D. Kukuruga, C.I. Drachenberg, R. Bluebond-Langner, H. Hui-Chou, S.T. Shipley, S.T. Bartlett, and E.D. Rodriguez, *Prolonged survival of composite* *facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder.* Transplantation, 2009. 88(11): p. 1242-50.
13. Gammie, J.S., S.T. Bartlett, and B.P. Griffith, *Small-incision mitral valve repair: safe, durable,*

*and approaching perfection.* Ann Surg, 2009. 250(3): p. 409-15.

Stephen Thomas Bartlett, M.D.



Page 26

1. Haririan, A., J. Nogueira, D. Kukuruga, E. Schweitzer, J. Hess, C. Gurk-Turner, S. Jacobs, C. Drachenberg, S. Bartlett, and M. Cooper, *Positive cross-match living donor kidney* *transplantation: longer-term outcomes.* Am J Transplant, 2009. 9(3): p. 536-42.
2. Kramer, A., J. Sausville, A. Haririan, S. Bartlett, M. Cooper, and M. Phelan, *Simultaneous* *bilateral native nephrectomy and living donor renal transplantation are successful for polycystic kidney disease: the University of Maryland experience.* J Urol, 2009. 181(2): p. 724-8.
3. Neschis, D.G., S. Moainie, W.R. Flinn, T.M. Scalea, S.T. Bartlett, and B.P. Griffith, *Endograft* *repair of traumatic aortic injury-a technique in evolution: a single institution's experience.* AnnSurg, 2009. 250(3): p. 377-82.
4. Nogueira, J.M., A. Haririan, S.C. Jacobs, M.R. Weir, H.A. Hurley, H.S. Al-Qudah, M. Phelan, C.B. Drachenberg, S.T. Bartlett, and M. Cooper, *The detrimental effect of poor early graft* *function after laparoscopic live donor nephrectomy on graft outcomes.* Am J Transplant, 2009.9(2): p. 337-47.
5. Nogueira, J.M., M.R. Weir, S. Jacobs, A. Haririan, D. Breault, D. Klassen, D. Evans, S.T. Bartlett, and M. Cooper, *A study of renal outcomes in African American living kidney donors.* Transplantation, 2009. 88(12): p. 1371-6.
6. Pradel, F.G., P. Suwannaprom, C.D. Mullins, J. Sadler, and S.T. Bartlett, *Haemodialysis patients'* *readiness to pursue live donor kidney transplantation.* Nephrol Dial Transplant, 2009. 24(4): p.1298-305.
7. Sener, A., E.J. Schweitzer, R. Munivenkatappa, M. Cooper, S.T. Bartlett, B. Philosophe, and R.N. Barth, *Deceased-donor renal transplantation in the geriatric population demonstrates* *equal graft survival compared with younger recipients.* Transplantation, 2009. 87(10): p. 1549-54.
8. Sener, A., V. Uberoi, S.T. Bartlett, A.C. Kramer, and M.W. Phelan, *Living-donor renal* *transplantation of grafts with incidental renal masses after ex-vivo partial nephrectomy.* BJU Int,2009. 104(11): p. 1655-60.
9. Bartlett, S.T., E.J. Schweitzer, and M. Cooper, *Prediction model for delayed kidney transplant* *function: no need for new regulation.* Am J Transplant, 2010. 10(10): p. 2191-2.
10. Nogueira, J.M., M.R. Weir, S. Jacobs, D. Breault, D. Klassen, D.A. Evans, S.T. Bartlett, and M. Cooper, *A study of renal outcomes in obese living kidney donors.* Transplantation, 2010. 90(9): p. 993-9.
11. Sener, A., M. Cooper, and S.T. Bartlett, *Is there a role for pancreas transplantation in type 2* *diabetes mellitus?* Transplantation, 2010. 90(2): p. 121-3.
12. Barth, R.N., E.D. Rodriguez, G.S. Mundinger, A.J. Nam, J.S. Ha, H. Hui-Chou, L.S. Jones, A. Panda, S.T. Shipley, C.B. Drachenberg, D. Kukuruga, and S.T. Bartlett, *Vascularized bone* *marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates.* Am J Transplant, 2011. 11(7): p. 1407-16.
13. Drachenberg, C.B., J.R. Torrealba, B.J. Nankivell, E.B. Rangel, I.M. Bajema, D.U. Kim, L. Arend, E.R. Bracamonte, J.S. Bromberg, J.A. Bruijn, D. Cantarovich, J.R. Chapman, A.B. Farris, L. Gaber, J.C. Goldberg, A. Haririan, E. Honsova, S.S. Iskandar, D.K. Klassen, E. Kraus, F. Lower, J. Odorico, J.L. Olson, A. Mittalhenkle, R. Munivenkatappa, S. Paraskevas, J.C. Papadimitriou, P. Randhawa, F.P. Reinholt, K. Renaudin, P. Revelo, P. Ruiz, M.D. Samaniego, R. Shapiro, R.J. Stratta, D.E. Sutherland, M.L. Troxell, L. Voska, S.V. Seshan, L.C. Racusen, and S.T. Bartlett, *Guidelines for the diagnosis of antibody-mediated rejection in pancreas* *allografts-updated Banff grading schema.* Am J Transplant, 2011. 11(9): p. 1792-802.
14. Gallagher, K.A., R.A. Ravin, E. Schweitzer, T. Stern, and S.T. Bartlett, *Outcomes and timing of* *aortic surgery in renal transplant patients.* Ann Vasc Surg, 2011. 25(4): p. 448-53.

Stephen Thomas Bartlett, M.D.



Page 27

1. Mundinger, G.S., A.J. Nam, H.G. Hui-Chou, M.G. Stanwix, L.S. Jones, C.B. Drachenberg, D. Kukuruga, S.T. Shipley, A.H. Dorafshar, A. Panda, S.T. Bartlett, R.N. Barth, and E.D. Rodriguez, *Nonhuman primate model of fibula vascularized composite tissue allotransplantation* *demonstrates donor-recipient bony union.* Plast Reconstr Surg, 2011. 128(6): p. 1193-204.
2. Bojovic, B., A.H. Dorafshar, E.N. Brown, M.R. Christy, D.E. Borsuk, H.G. Hui-Chou, C.K. Shaffer, T.N. Kelley, P.J. Sauerborn, K. Kennedy, M. Hyder, P.S. Brazio, B. Philosophe, R.N. Barth, T.M. Scalea, S.T. Bartlett, and E.D. Rodriguez, *Total face, double jaw, and tongue* *transplant research procurement: an educational model.* Plast Reconstr Surg, 2012. 130(4): p.824-34.
3. Fayek, S.A., J. Keenan, A. Haririan, M. Cooper, R.N. Barth, E. Schweitzer, J.S. Bromberg, S.T. Bartlett, and B. Philosophe, *Ureteral stents are associated with reduced risk of ureteral* *complications after kidney transplantation: a large single center experience.* Transplantation,2012. 93(3): p. 304-8.
4. Harbell, J., J. Fung, N. Nissen, K. Olthoff, S.S. Florman, D.W. Hanto, J. Light, S.T. Bartlett, A.G. Tzakis, T.C. Pearson, B. Barin, M.E. Roland, and P.G. Stock, *Surgical complications in* *275 HIV-infected liver and/or kidney transplantation recipients.* Surgery, 2012. 152(3): p. 376-81.
5. Mundinger, G.S., M. Narushima, H.G. Hui-Chou, L.S. Jones, J.S. Ha, S.T. Shipley, C.B. Drachenberg, A.H. Dorafshar, I. Koshima, S.T. Bartlett, R.N. Barth, and E.D. Rodriguez, *Infrared fluorescence imaging of lymphatic regeneration in nonhuman primate facial vascularized composite allografts.* Ann Plast Surg, 2012. 68(3): p. 314-9.
6. Seshadri, A., C. Byrne, A. Kramer, S.T. Bartlett, and R. Sarkar, *Revascularization and rescue of* *a failed kidney transplant in a case of autosomal dominant polycystic kidney disease.* J VascSurg, 2012. 55(6): p. 1766-8.
7. Shi, Q., J.R. Lees, D.W. Scott, D.L. Farber, and S.T. Bartlett, *Endogenous expansion of* *regulatory T cells leads to long-term islet graft survival in diabetic NOD mice.* Am J Transplant,2012. 12(5): p. 1124-32.
8. Weir, M.R., S.T. Bartlett, and C.B. Drachenberg, *Eosinophilia as an early indicator of* *pancreatic allograft rejection.* Clin Transplant, 2012. 26(2): p. 238-41.
9. Barth, R.N., M.W. Phelan, L. Goldschen, R.B. Munivenkatappa, S.C. Jacobs, S.T. Bartlett, and B. Philosophe, *Single-port donor nephrectomy provides improved patient satisfaction and* *equivalent outcomes.* Ann Surg, 2013. 257(3): p. 527-33.
10. Brazio, P.S., R.N. Barth, B. Bojovic, A.H. Dorafshar, J.P. Garcia, E.N. Brown, S.T. Bartlett, and E.D. Rodriguez, *Algorithm for total face and multiorgan procurement from a brain-dead donor.* Am J Transplant, 2013. 13(10): p. 2743-9.
11. Brazio, P.S., R.B. Munivenkatappa, B. Bojovic, J.S. Ha, E.N. Brown, A.S. Hess, S.T. Bartlett, E.D. Rodriguez, and R.N. Barth, *Regulatory T cells are not predictive of outcomes in a* *nonhuman primate model of vascularized composite allotransplantation.* Transplantation, 2013.96(3): p. 267-73.
12. Dorafshar, A.H., B. Bojovic, M.R. Christy, D.E. Borsuk, N.T. Iliff, E.N. Brown, C.K. Shaffer, T.N. Kelley, D.L. Kukuruga, R.N. Barth, S.T. Bartlett, and E.D. Rodriguez, *Total face, double* *jaw, and tongue transplantation: an evolutionary concept.* Plast Reconstr Surg, 2013.**131**(2): p.241-51.
13. Mullins, C.D., R. Jain, M.R. Weir, C.S. Franey, Y.C. Shih, F.G. Pradel, K. Bikov, and S.T. Bartlett, *Benefits Improvement and Protection Act's impact on transplantation rates among* *elderly MEDICARE beneficiaries with end-stage renal disease.* Transplantation, 2013.**95**(3): p.463-9.

Stephen Thomas Bartlett, M.D.



Page 28

1. Mundinger, G.S., R. Munivenkatappa, C.B. Drachenberg, J.S. Ha, E.E. Vaca, S.T. Shipley, J.C. Papadimitriou, S.T. Bartlett, E.D. Rodriguez, and R.N. Barth, *Histopathology of chronic* *rejection in a nonhuman primate model of vascularized composite allotransplantation.* Transplantation, 2013. **95**(10): p. 1204-10.
2. Scalea, J.R., J. Menaker, A.K. Meeks, M.E. Kramer, J.A. Kufera, K.M. Auman, M. Cooper, S.T. Bartlett, and T.M. Scalea, *Trauma patients with a previous organ transplant: outcomes are* *better than expected-a retrospective analysis.* J Trauma Acute Care Surg, 2013.**74**(6): p. 1498-503.
3. Schultz BD, Woodall J, Brazio PS, Uluer MC, Kukuruga DL, Azimzadeh AA, Bojovic B, Rodriguez ED, Bartlett ST, Barth RN. *Early Microchimerism after Face Transplantation*

*Detected by Quantitative Real-Time Polymerase Chain Reaction of Insertion/Deletion Polymorphisms.* Transplantation 2015 Jul;99(7):e44-5.Brazio PS, Woodall J, Panda A, BrownEN, Ha JS, Azimzadeh AM, Rodriguez ED, Bartlett ST, Bojovic B, Barth RN. *Infused bone* *marrow fails to prevent vascularized composite allograft rejection in nonhuman primates.* American Journal of Transplantation 2015 Jul;15(7):2011-2.

1. Scalea JR, Bromberg J, Bartlett ST, Scalea TM. *Mechanistic similarities between trauma,* *atherosclerosis, and other inflammatory processes*. J Crit Care. 2015 Dec;30(6):1344-8. Epub2015 Jul 29. Review. PubMed PMID: 26304513.
2. Woodall JD, Uluer MC, Chrencik MT, Nam AJ, Bartlett ST, Barth RN. *Lost in translation?* *Microchimersim detection in experimental and clinical transplantation*. Chimerism. 2015 Oct2;6(4):51-53. Review. PubMed PMID: 27996370; PubMed Central PMCID: PMC5293316.
3. Bartlett ST, Markmann JF, Johnson P, Korsgren O, Hering BJ, Scharp D, Kay TW, Bromberg J, Odorico JS, Weir GC, Bridges N, Kandaswamy R, Stock P, Friend P,Gotoh M,

Cooper DK, Park CG, OʼConnell P, Stabler C, Matsumoto S, Ludwig B, Choudhary P, Kovatchev B, Rickels MR, Sykes M, Wood K, Kraemer K, Hwa A, Stanley E, Ricordi C, Zimmerman M, Greenstein J, Montanya E, Otonkoski T. *Report from IPITA-TTS Opinion* *Leaders Meeting on the Future of β-Cell Replacement. Transplantation*. 2016 Feb;100 Suppl2:S1-44. PubMed PMID: 26840096; PubMed Central PMCID: PMC4741413.

1. Ahmad SB, Inouye B, Phelan MS, Kramer AC, Sulek J, Weir MR, Barth RN, LaMattina JC,chweitzer EJ, Leeser DB, Niederhaus SV, Bartlett ST, Bromberg JS. *Live Donor Renal* *Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up. Transplantation*. 2016Feb;100(2):407-15. PubMed PMID: 26262506; PubMed Central PMCID:PMC4896313.
2. Scalea TM, Rubinson L, Tran Q, Jones KM, Rea JH, Stein DM, Bartlett ST, O'Connor JV. *Critical Care Resuscitation Unit: An Innovative Solution to Expedite Transfer of Patients with Time-Sensitive Critical Illness*. J Am Coll Surg. 2016 Apr;222(4):614-21.Epub 2016 Feb 23.PubMed PMID: 26920992.
3. Parimi N, Hu PF, Mackenzie CF, Yang S, Bartlett ST, Scalea TM, Stein DM. *Automated* *continuous vital signs predict use of uncrossed matched blood and massive transfusion following trauma. J Trauma Acute Care Surg.* 2016 Jun; 80(6):897-906. PubMed PMID: 27027555.
4. Markmann JF, Bartlett ST, Johnson P, Korsgren O, Hering BJ, Scharp D, Kay TW, Bromberg J, Odorico JS, Weir GC, Bridges N, Kandaswamy R, Stock P, Friend P, Gotoh M, Cooper DK,

Park CG, OʼConnell PJ, Stabler C, Matsumoto S, Ludwig B, Choudhary P, Khovatchev B, Rickels MR, Sykes M, Wood K, Kraemer K, Hwa A, Stanley E, Ricordi C, Zimmerman M, Greenstein J, Montanya E, Otonkoski T. *Executive Summary of IPITA-TTS Opinion Leaders*

*Report on the Future of β-Cell Replacement.* Transplantation. 2016 Jul;100(7):e25-31. Review.PubMed PMID: 27082827.

Stephen Thomas Bartlett, M.D.



Page 29

1. Ahmad SB, Miller M, Hanish S, Bartlett ST, Hutson W, Barth RN, LaMattina JC. *Sequential* *kidney-liver transplantation from the same living donor for lecithin cholesterol acyl transferase deficiency.* Clin Transplant. 2016 Oct;30(10):1370-1374. Epub 2016 Sep 24. PubMed PMID:27490864.
2. Hanish SI, Stein DM, Scalea JR, Essien EO, Thurman P, Hutson WR, Bartlett ST, Barth RN, Scalea TM. *Molecular Adsorbent Recirculating System Effectively Replaces Hepatic Function in* *Severe Acute Liver Failure.* Ann Surg. 2017 Oct; 266(4):677-684. PubMed PMID: 28692474.
3. Scalea JR, Sultan S, Lamos EM, Bartlett ST, Barth RN. *Improvement in pancreas transplant* *evaluation and surgical volume using a multidisciplinary approach.* Am J Transplant. 2017 Nov22 PubMed PMID: 29166550.
4. Scalea JR, Pettinato L, Fiscella B, Bartosic A, Piedmonte A, Paran J, Todi N, Siskind EJ, Bartlett ST. *Successful pancreas transplantation alone is associated with excellent self-identified health* *score and glucose control: A retrospective study from a high-volume center in the United States.* Clin Transplant. 2018 Feb;32(2).PubMed PMID: 29226480.
5. Ravichandran BR, Gillespie MW, Sparkes TM, Williams C, Bartlett ST, HaririanA, Masters BM. *Collaborative practice agreement in solid organ transplantation*. Int J Clin Pharm. 2018 Feb21.PubMed PMID: 29468527.
6. Sparkes T, Manitpisitkul W, Masters B, Bartlett ST, Davis C, Husson J, Amoroso A, Haririan A. Impact of antiretroviral regimen on renal transplant outcomes in HIV-infected recipients. Transpl Infect Dis. 2018 Sep 5:e12992. doi:

10.1111/tid.12992. [Epub ahead of print] PubMed PMID: 30184310.

1. Scalea JR, Restaino S, Scassero M, Bartlett ST, Wereley N. The final frontier? Exploring organ transportation by drone. Am J Transplant. 2018 Sep 11. doi: 10.1111/ajt.15113. [Epub ahead of print] PubMed PMID: 30203436.
2. Ngaage LM, Elegbede A, Tadisina KK, Gebran SG, Masters BM, Rada EM, Nam AJ, Scalea JR, Niederhaus SV, Singh D, Bromberg JS, Bartlett ST, Rasko YM. Panniculectomy at the time of living donor renal transplantation: An 8-year experience. Am J Transplant. 2019 Aug;19(8):2284-2293. doi: 10.1111/ajt.15285.Epub 2019 Mar 2. PubMed PMID: 30720924.
3. Boggi U, Vistoli F, Andres A, Arbogast HP, Badet L, Baronti W, Bartlett ST, Benedetti E, Branchereau J, Burke GW 3rd, Buron F, Caldara R, Cardillo M, Casanova D, Cipriani F, Cooper M, Cupisti A, Davide J, Drachenberg C, de Koning EJP, Ettorre GM, Fernandez Cruz L, Fridell JA, Friend PJ, Furian L, Gaber OA, Gruessner AC, Gruessner RWG, Gunton JE, Han DJ, Iacopi S, Kauffmann EF, Kaufman D, Kenmochi T, Khambalia HA, Lai Q, Langer RM, Maffi P, Marselli L, Menichetti F, Miccoli M, Mittal S, Morelon E, Napoli N, Neri F, Oberholzer J, Odorico JS, Öllinger R, Oniscu G, Orlando G, Ortenzi M, Perosa M, Perrone VG, Pleass H, Redfield RR, Ricci C, Rigotti P, Paul Robertson R, Ross LF, Rossi M, Saudek F, Scalea JR, Schenker P, Secchi A, Socci C, Sousa Silva D, Squifflet JP, Stock PG, Stratta RJ, Terrenzio C, Uva P, Watson CJE, White SA, Marchetti P, Kandaswamy R, Berney T. First World Consensus Conference on pancreas transplantation: Part II - recommendations. Am J Transplant. 2021 Sep;21 Suppl 3(Suppl 3):17-59. doi: 10.1111/ajt.16750. Epub 2021 Jul 29. PMID: 34245223; PMCID: PMC8518376.

**NON-PEER REVIEWED ARTICLES**

1. **Bartlett ST**, Naji A, Silvers WK, Barker CF. Major histocompatibility complex restriction inendocrine allograft immunity. Surgical Forum 24:406-408, 1984.
2. Chin T, Hadley GA, **Bartlett ST**. Adhesion molecule expression on CD8 positive T cells infiltrating renal allografts. Surgical Forum 45:198-202, 1995.
3. Sutherland DER, **Bartlett ST**, Gaber AO, Stock P. Symposium: Pancreas Transplantation. Contemporary Surgery 51(4):253-272, 1997.
4. Johnson LB, Kuo PC, Schweitzer, **Bartlett ST**, et al. Double adult renal allografts. Trans Rev 12:59-63, 1998.
5. **Bartlett ST**. Techniques of pancreatic duct implantation.Current Opinion in OrganTransplantation 3:248-252, 1998.
6. **Bartlett ST**, Schweitzer EJ. Laparoscopic living donor nephrectomy for kidney transplantation:The University of Maryland Experience. Dialysis & Transplantation 28(6) 318-331, 1999.

Stephen Thomas Bartlett, M.D. Page 30



1. Connerney I, Evans DE, Ange M, Compton O, **Bartlett ST**. Laparoscopic nephrectomy program boosts successful outcomes at University. Inside Case Management 6(2);1-7, 1999.
2. **Bartlett ST**. The laparoscopic donor nephrectomy provides good quality kidneys.Transplantation&Immunology Letter Volume XV, No. 3, 1999.
3. Keay Susan, Oldach David, Redfield R, **Bartlett ST**. Organ transplantation in the HIV-infected patient.Current Opinion in Transplantation Volume X, No. 3, 2000.
4. **Bartlett ST**. Pancreas and Islet Transplantation.Transplantation 2000 - Progress at theMillennium. p. 8-9, 2000.
5. Farney AC, **Bartlett ST**. Pancreas transplantation: Still the number one transplant option for people with type I diabetes. Insulin Free Times. 2001.
6. Leeser DL, **Bartlett ST**. Surgical issues in the transplant patient. Medical management of kidney transplantation. 2004*.*

**BOOK CHAPTERS**

1. **Bartlett ST** and Blaisdell FW. Is there a case for early amputation for critical ischemia:, p. 389-
   1. In R.M. Greenhalgh, C.W. Jamieson and A.N. Nicolaides (Eds.), Limb Salvage and Amputation for Vascular Disease. W.B. Saunders, Philadelphia, PA. 1988
2. **Bartlett ST** and Blaisdell FW. Abdominal vascular injuries:,p. 236-240.In Current Therapy ofTrauma. D.D. Trunkey, F.R. Lewis (Eds.), B.C. Decker, Philadelphia, PA. 1991.
3. **Bartlett ST** and Hadley GA. Cellular interactions in pancreas and islet Transplantation:, p. 161-
   1. Cellular Inter-Relationships. L. Rosenberg and W.P. Duguid (Eds.) R.G. Landes Company,

1996

1. **Bartlett ST**. The Older Donor; p. 490–502.Organ Transplantation. F.P. Stuart, M. M.Abecassis, D. B. Kaufman (Eds.), R.G. Landes Company, Georgetown, Texas, 2000.
2. **Bartlett ST**. Pancreas and Islet Transplantation; 617-632.Surgery: Scientific Principals andPractice, 3rd edition. Greenfield, Lillemoe, Mulholland, Oldham and Zelenock (Eds.), Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2001.
3. Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE, Foster CE, Wiland AM, **Bartlett** **ST**. Simultaneous Pancreas-Kidney and pancreas-living donor kidney (SPLK) transplantation atthe University of Maryland. Clinical Transplant 2000. Cecka and Terasaki (Eds.), UCLA Tissue Typing Laboratory, Los Angeles, CA, 2001.
4. Krishnamurthi V, Philosophe B, **Bartlett ST**. Pancreas transplantation: contemporary surgical techniques. Urol Clin North Am 2001; 28(4):833-838.
5. Krishnamurthi V and **Bartlett ST**. Surgical techniques of pancreas transplantation. Pancreas and

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
| Islet Transplantation. | | Hakim, Stratta and Gray (Eds.), Oxford Medical Publications, United | |
| Kingdom, 2002. |  |  |  |

Stephen Thomas Bartlett, M.D. Page 31



1. Jacobs SC and **Bartlett ST**. Laparoscopic donor nephrectomy; 984-994. ACS Surgery Principles & Practice 2003. Wimore, Cheung, Harken, Holcroft, Meakins and Soper (eds.), WebMD Professional Publishing, New York, NY, 2003.

**ABSTRACTS**

1. **Bartlett ST,** Kaplan EL. Serum calcium changes after parathyroidectomy for primaryhyperthyroidism. International Association of Endocrine Surgeons, 1979.
2. **Bartlett ST**, Kaplan EL. Serum calcium changes after thyroid surgery. American Association ofEndocrine Surgeons, May 5, 1980.
3. Gatti JO and **Bartlett ST**. Comparison of wound debridement enzyme vs. wet to dry dressing. Robert H. Ivy Society, February, 1981.
4. **Bartlett ST** and Kaplan EL. Post-operative serum calcium values following different parathyroidoperations. American Association of Endocrine Surgeons, April 6, 1982.
5. **Bartlett ST**, Naji A, Silvers WK, Barker CF. The role of histocompatibility in cultured isletallograft survival. Diabetes, 32:572 1983.
6. **Bartlett ST**, Naji A, Silvers WK, Barker CF. Major histocompatibility complex restriction in isletallograft immunity. American Society of Transplant Surgeons, June 2, 1983.

|  |  |
| --- | --- |
| 7. | **Bartlett ST**, Naji A, Silvers WK, Barker CF. The role of major histocompatibility complex |
|  | restriction in cultured islet transplants. International Symposium on Organ Transplantation in |
|  | Diabetes, September 2, 1983. |

1. **Bartlett ST**, Barker CF. Major histocompatibility complex restriction islet allograft immunity.Society of Clinical Surgery, October 13, 1983.
2. **Bartlett ST**, Barker CF. Established islet allografts induce partial unresponsiveness to donorantigens. Society of University Surgeons, Resident's Conference, February 6, 1984.
3. **Bartlett ST**, McCarthy WJ. Laser induced arterial aneurysms. Chicago Vascular SurgeryResearch Symposium, June 7, 1986.
4. **Bartlett ST**, Olinde AJ, Flinn WR, McCarthy WJ, Fahey VA, Bergan JJ, Yao JST. The re-operative potential of infrainguinal bypass; Long term limb and patient survival. Society for Vascular Surgery, June 9, 1986.
5. Stept LL, Flinn WR, McCarthy III WJ, **Bartlett ST**, Bergan JJ, and Yao JST. Technical defects as a cause of early graft failure after femorodistal bypass. Western Surgical Association 94th Annual Meeting, 1986.

Stephen Thomas Bartlett, M.D. Page 32



1. **Bartlett ST**, Killewich LA, Fisher C. Tibial artery and distal anastomotic duplex imaging after insitu saphenous vein bypass. San Diego Symposium on Non-Invasive Diagnostic Techniques in Vascular Disease, February 22-26, 1988.
2. **Bartlett ST**, Ward RE. Long term survival of MHC-compatible and incompatible pancreaticallografts in BB rats with cyclosporine. 12th Annual Meeting Western Association of Transplant Surgeons, March 4, 1988.
3. **Bartlett ST**, Killewich LA, Fisher C, Ward RE. Duplex imaging of in situ saphenous vein bypassgrafts prevents late failure. The Southwestern Surgical Congress 40th Annual Meeting, April 10-16, 1988.
4. **Bartlett ST**, Aoki TT. Survival of pancreatic transplants in BB rats is not MHC- restricted.Diabetes. Vol. 37 supplement 1 p. 212A, 1988.
5. Gillison SL, **Bartlett ST**, Curry DL. The in vitro perfused pancreas: A model for rigorous comparison on pancreatic transplant techniques. XII International Congress of the Transplantation Society, Sydney, Australia, August 14-19, 1988.
6. Ward RE, **Bartlett ST**, Koenig J, Ballenger J, Neylan J, Friend M. The use of duplex scanning in evaluation of the post-transplant kidney. XII International Congress of the Transplantation Society, Sydney, Australia, August 14-19, 1988.
7. Dugoni WE, Ward RE, **Bartlett ST**. Improved results with surgical treatment of renovascular hypertension. The Journal of Cardiovascular Surgery, 30 (Suppl.):54, 1989.
8. Killewich LA, Fisher C, **Bartlett ST**. Color flow duplex for in situ bypass surveillance: Is the increased cost worthwhile? The Journal of Cardiovascular Surgery, 30 (Suppl.):75, 1989.
9. **Bartlett ST**, Dugoni WE, Gillison SL, Curry DL. The in vitro perfused pancreas: a model forrigorous comparison of pancreatic transplant techniques. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, September 17-22, 1989.
10. **Bartlett ST**, Gillison SL, Dugoni DE, Curry DL. The mechanism of cyclosporine inhibition ofinsulin secretion. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, September 17-22, 1989.
11. Dugoni WE, **Bartlett ST**. Cyclosporine prevents recurrent diabetes in pancreas transplants. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, September 17-22, 1989.
12. Dugoni WE, Ward RE, **Bartlett ST**. The effect of histocompatibility matching in pancreas transplantation: A rodent model using congenic histocompatible strains. 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, September 17-22, 1989.
13. Thayer C, **Bartlett ST**, Ward RE. Increased septic complications with 3 drug sequential immunosuppression for cadaver renal transplants. The Southwestern Surgical Congress, La Quinta, California, April 22-25, 1990.
14. Killewich LA, **Bartlett ST**. The "all-autogenous" tissue policy for infrainguinal reconstruction questioned. The Southwestern Surgical Congress, La Quinta, California, April 22-25, 1990.

Stephen Thomas Bartlett, M.D. Page 33



1. **Bartlett ST**, Killewich LA. Recurrent diabetes in pancreas transplants in the BB rat: Evidence foran intrinsic pancreatic defect. XIII International Congress of The Transplantation Society, San Francisco, California, August 19-24, 1990.
2. **Bartlett ST**. Behcet's Disease. American College of Surgeons Postgraduate Course in VascularSurgery, Palm Springs, California, March 15-17, 1991.
3. **Bartlett ST**, Killewich LA. Color Flow Duplex. Palm Springs, California, March 15-17, 1991.
4. **Bartlett ST**. Renovascular Hypertension. Palm Springs, California, March 15-17, 1991.
5. Gillison SL, **Bartlett ST**, Curry DL. Cyclosporine inhibits translation initiation of preproinsulin in RNA. 3rd International Congress on Pancreatic and Islet Transplantation, Lyon, France, June 6-8, 1991.
6. **Bartlett ST**, Killewich LA. Gamma INF Induction of MHC Class II does not confer susceptibilityto recurrent diabetes in pancreas transplants in the BB rat. 3rd International Congress on Pancreatic and Islet Transplantation, Lyon, France, June 6-8, 1991.
7. **Bartlett ST**, Gillison SL, Dirden BA, Curry DL. Long term pancreatic and pancreaticoduodenalisografts maintain normal insulin secretory function in Lewis rats. 3rd International Congress on Pancreatic and Islet Transplantation, Lyon, France, June 6-8, 1991.
8. **Bartlett ST**, Schweitzer EJ, Evans D, Matthew R, Hands LB. Impact of HIV Infection Acquiredin the Post Transplant Period. XIV International Congress Transplantation Society, 1992.
9. **Bartlett ST**, Schweitzer EJ. Impact of Hepatitis B or C Infection on the Practice of KidneyTransplantation in the USA. XIV International Congress of the Transplantation Society, 1992
10. **Bartlett ST**, Schweitzer EJ, Dirden BA. Islet but not Whole Pancreas Transplant are Susceptibleto Recurrent Autoimmunity. XIV International Congress of the Transplantation Society, 1992.
11. **Bartlett ST**, Schweitzer EJ, Dirden BA. Islet but not Whole Pancreas Transplant are Susceptibleto Recurrent Autoimmunity. American Society of Transplant Physicians, 1992.
12. **Bartlett ST**, Schweitzer EJ, Dirden BA. Islet but not Whole Pancreas Transplant are Susceptibleto Recurrent Autoimmunity. American Diabetes Association, 1992.
13. **Bartlett ST**, Schweitzer EJ, Hadley GA, Dirden BA. Islet but not Whole Pancreas Transplants areSusceptible to Recurrent Autoimmunity. Pancreas Club, 1992
14. **Bartlett ST**, Schweitzer EJ, Dirden BA, Hadley GA. Islets Transplants but not Whole Pancreas isSusceptible to Recurrent Autoimmunity. Transplantation Congress, 1992.
15. Keay S, Behrens MT, Klassen DK, Weir MR, Schweitzer EJ, Evans D, Constantine NT, **Bartlett** **ST**. Impact of Asymptomatic HIV-1 infection on renal allograft recipients.
16. Schweitzer EJ, **Bartlett ST**, Keay S, Hadley GA, Cregor GA, Stockdreher DD. Impact of Hepatitis B or C infection on the practice of Kidney Transplantation. Transplantation Congress, 1992.

Stephen Thomas Bartlett, M.D. Page 34



1. **Bartlett ST**, Schweitzer EJ, Dirden BA, Hadley GA. Islet transplants but now whole pancreas aresusceptible to recurrent autoimmunity. Transplantation Congress, 1992.
2. **Bartlett ST**, Schweitzer EJ, Hadley GA. Protection from autoimmunity by Kidney-Islettransplantation does not require direct islet inoculation to the co-transplanted kidney. International Congress on Pancreas and Islet Transplantation, 1993.
3. Schweitzer EJ, **Bartlett ST**. Wound complications with pancreas transplant through a kidney transplant incision. International Congress on Pancreas and Islet Transplantation, 1993.
4. Hadley GA and **Bartlett ST**. Tissue-restricted T-cell allorecognition. Journal of Immunology, 150(8):190a, 1993.
5. **Bartlett ST**, Dirden BA, Schweitzer EJ, Hadley GA. Composite renal-islet transplantationprevents autoimmune beta cell destruction. The Society of University Surgeons, 1993.
6. Sheffield C, Hadley GA, **Bartlett ST**. Intrathymic injection of donor splenocytes prolongs heart

xenograft survival in a hamster-to-rat transplant model. International Congress of Xenotransplantation, 1993.

1. Hadley GA and **Bartlett ST**. Tissue-restricted T-cell allorecognition. Third Basic Sciences Symposium of the International Transplant Congress, 1993.
2. Hadley GA, Rostapshova E, **Bartlett ST**. CTL raised against allogenic kidney cells are

functionally and phenotypically distinct from conventional alloreactive CTL populations.

American Society of Transplant Surgeons, 1994.

1. Walker JA, Weir MR, Klassen DK, Dunston R, Schweitzer EJ, **Bartlett ST**. Late pancreatic rejection: Inadequacy of current laboratory screening and importance of cyclosporine (CSA) levels. American Journal Society of Nephrology, 1994;5:1043.
2. Weir MR, Malinow L, Klassen DK, Schweitzer EJ, **Bartlett ST**. A comparison of the incidence of delayed renal allograft function with OKT3, intra-operatively (10p) or post-operatively (POp), vs. polyclonal antilymphocyte globulin. American Journal Society of Nephrology, 1994;5:1043.
3. Weir MR, Klassen DK, Johnson LB, Schweitzer EJ, **Bartlett ST**. Isolated pancreas graft rejection in combined kidney pancreas transplantation: Clinical results of percutaneous biopsy. American Society of Nephrology, 1994.
4. Papadimitriou JC, Drachenberg CB, Phelps PC, **Bartlett ST**, Trump BF, Hadley GA. Comparison between terminal complement complex (TCC) and alloreactive cytolytic T cell (CTL) mediated renal epithelial cell injury. 5th European Meeting in Complement in Human Disease, Les Diablerets, Switzerland, September, 1994. Clin Exper Immunol 1994, 97 (Suppl 2), 38
5. Papadimitriou JC, Drachenberg CB, Phelps PC, **Bartlett ST**, Trump BF, Hadley GA. Alloreactive cytolytic T cells produce an intermediate pattern between apoptosis and necrosis in kidney epithelial target cells. XX International congress of the International Academy of Pathology and 11th World Congress of Academic and Environmental Pathology, Hong Kong, October, 1994). Int J Surg Patho, 1995, 2(Suppl), 558.
6. **Bartlett ST**, Chin T, Dirden B, Quershi A, Hadley G. Inclusion of peripancreatic lymph node cellsprevents recurrent autoimmune destruction of islet transplants: Evidence of donor chimerism. Society of University Surgeons. Denver, Colorado. February 9-11, 1995.

Stephen Thomas Bartlett, M.D. Page 35



1. Wong-You-Cheong JJ, Krebs T, Daly B, Simon E, **Bartlett ST**, Johnson LB. MR assessment of complications of pancreatic and renal transplantation with a phased array surface coil. Roentgen Centenary Congress, Birmingham, UK, June,1995.
2. Schweitzer EJ, Drachenberg C, Anderson L, Papadimitriou J, Johnson LB, Klassen D, **Bartlett ST**. Significance of the banff borderline biopsy. American Society of Transplant Surgeons, Chicago, Illinois, May 17-19,1995.
3. Walker JA, Klassen DK, Hoehn-Saric EW, Hooper FJ, Schweitzer EJ, Johnson LB, **Bartlett ST**, Weir MR. Acute pancreas allograft rejection after the first year: Predisposing factors. American Society of Transplant Surgeons, Chicago, Illinois, May 17-19,1995.
4. Hoehn-Saric EW, Wiland A, Weir MR, Klassen DK, Schweitzer EJ, Johnson LB, **Bartlett ST**. Initial experience with tacrolimus as rescue therapy for refractory pancreatic allograft rejection. American Society of Transplant Surgeons, Chicago, Illinois, May 17-19, 1995.
5. Wiland A, Schweitzer EJ, Johnson LB, Anderson L, Klassen DK, Weir MR, **Bartlett ST**. Omission of anti-thymocyte globulin (ATG) induction in haplo- and non-identical living donor transplants prolongs initial hospitalization. American Society of Transplant Surgeons, Chicago, Illinois, May 17-19,1995.
6. Klassen DK, Papadimitriou JC, Drachenberg CB, Mayuga RS, Walker JA, Hooper FJ, Hoehn-Saric EW, Schweitzer EJ, **Bartlett ST**, Weir MR. A proposed histologic grading system for acute pancreas allograft rejection: A predictor of graft survival. American Society of Transplant Surgeons, Chicago, Illinois, May 17-19, 1995. (Oral presentation).
7. Johnson LB, Shaffer D, McNally D, Schweitzer EJ, **Bartlett ST**, Weir MR, Klassen DK, Hoehn-Saric EW, Washburn K, Simpson M, Conway P, Monaco A. Urinary trypsinogen activation peptides (TAP) signal proteolytic enzyme activation in recipients of pancreas allografts and predicts acute allograft rejection. Fifth International Congress on Pancreas and Islet Transplantation. Miami, Florida, June, 1995.
8. **Bartlett ST**, Schweitzer EJ, Johnson LB, Dirden BA, Anderson L, Quereshi A, Hadley GA.Homing to gut associated lymphoid tissue (galt) of a donor t cell subset associated with protection from autoimmunity in pancreas transplanted BB rats. Fifth International Congress on Pancreas and Islet Transplantation. Miami, Florida, June, 1995.
9. Walker JA, Klassen DK, Hoehn-Saric EW, Hooper FJ, Schweitzer EJ, Johnson LB, **Bartlett ST**, Weir MR. Acute pancreas allograft rejection after the first year; predisposing factors. Fifth International Congress on Pancreas and Islet Transplantation. Miami, Florida, June, 1995.
10. Chin TC, **Bartlett ST**, Rostapshova EA, Yeatman MT, Hadley GA. Differential regulation of CD11a (LFA-1) and CD49d (VLA-4) on CD8+ CTL that infiltrate acutely rejecting renal allografts. Fourth Basic Sciences Symposium of the Transplantation Society, The Netherlands, 1995.
11. Chin TC, **Bartlett ST**, Hadley GA. Accessory molecule expression on CD8+ T cells infiltrating renal allografts. American College of Surgeons, New Orleans, Louisiana, October 23-27,1995.
12. **Bartlett ST**, Dirden BA, Quereshi A, Hadley GA. Inclusion of peripancreatic lymph node cellsprevents recurrent autoimmune destruction of islet transplant: Evidence of donor chimerism. Society of University Surgeons, 1995.

Stephen Thomas Bartlett, M.D. Page 36



1. Krebs TL, Daly BD, Wong JJ, **Bartlett ST**. The MR derived pancreas to psoas ratio (PPR): Objective and reliable non-invasive diagnosis of pancreatic rejection. Fifth International Pancreas and Islet Transplantation Congress, 1995.
2. Drachenberg CB, Klassen DK, Papadimitriou JC, Weir MR, Hoehn-Saric E, Light P, Ramos E, Kuo PC, Schweitzer EJ, Johnson LB, Haines D, **Bartlett ST**. Histologic findings in islets of pancreatic allografts: Lack of evidence for recurrent cell mediated diabetes mellitus. American Society of Transplant Physicians. Dallas, TX, May 26-30, 1996.
3. Klassen DK, Hoehn-Saric E, Weir MR, Light P, Schweitzer EJ, Johnson LB, Kuo PC, **Bartlett ST**, Papadimitriou JC, Drachenberg CB. Occult kidney rejection in simultaneous kidney/pancreas transplantation. American Society of Transplant Physicians, Dallas, TX, May 26-30, 1996.
4. Papadimitriou JC, Klassen DK, Ioffe O, **Bartlett ST**, Ramos E, Hebel R, Drachenberg CB. Identification of histological features differentiating pancreatic allograft rejection from non-rejection related pathology. International Transplantation Society, Barcelona, Spain, August, 1996.
5. Papadimitriou JC, Makhouf HR, Bickel C, Trifillis A, Cui X, Hadley GA, **Bartlett ST**, Weir MR and Drachenberg CB. Comparative ultrastructural studies of cytotoxic T lymphocyte and eosinophil/renal tubular cell interaction: Implication for renal transplantation. XXI International Congress of the International Academy of Pathology and 12th World Congress of Academic and Environmental Pathology, Budapest, Hungary, October, 1996. Inter J Surg Path
6. **Bartlett ST**, Kuo PC, Lim JW, Johnson LB, Schweitzer EJ. HLA matching is unnecessary insolitary pancreas transplantation. The American Society of Transplant Surgeons, Chicago, Illinois. May 14-16, 1997.
7. Jacobs SC, **Bartlett ST**, Lim JW, Cho E, Schweitzer EJ, Kuo PC, Johnson LB, Plotkin JS, Flowers JL. Donor and recipient outcomes following laparoscopic donor nephrectomy. The American Society of Transplantation Surgeons, Chicago, Illinois. May 14-16, 1997.
8. Jacobs SC, **Bartlett ST**, Flowers JL. A 17 month experience with laparoscopic living donor nephrectomy. 15th World Congress on Endourology, Edinburgh, Scotland, UK. August 30-September 3, 1997. 1st prize best presentation.
9. Hadley GA, Rostapshova EA, **Bartlett ST**, Burns J. Dominant roles of CD103 & CD11a in determining the tissue specificity of CD8+ CTL. American Society of Transplant Surgeons, 1997.
10. Hadley GA, Rostapshova EA, **Bartlett ST**, Burns J. Differential integrin expression as a novel mechanism of tissue-restricted allorecognition by CD8+ CTL. Basic Sciences Symposium of the Transplantation Society, 1997.
11. Krebs TL, Daly BD, Wong-You-Cheong JJ, Fertakos RJ, **Bartlett ST**. Detection of pancreatic transplant rejection: Evaluation of two MR imaging techniques compared with histology. Radiology 205:1196, suppl, 1997.
12. Drachenberg CB, Abruzzo LV, Kumar D, **Bartlett ST**, Klassen DK, Johnson LB, Kuo PC, Schweitzer EJ, Papadimitriou JC. EBV-associated post-transplant lymphoproliferative disorder (PTLD) in pancreas allografts: Histologic diagnosis. Lab Inv 76(1):841, 1997.
13. Fowler BZ, Rostapshova EA, **Bartlett ST**, Hadley GA. Induction of the epithelial-specific integrin, CD103 on activated CD8 cells subsequent to their migration into renal allografts. International Congress of the Transplant Society, 1998.

Stephen Thomas Bartlett, M.D. Page 37



1. Krebs TL, Johnson BG, Daly BD, Wong-You-Cheong J, **Bartlett ST**. Percutaneous management of complications of renal and renal-pancreas transplant recipients using CT fluoroscopy (CTF): A two-year experience. Radiology 209P:1583, suppl, 1998.
2. Meador TL, Krebs TL, Wong-You-Cheong JJ, post-transplant lymphoproliferative disorder Radiology 209P:1585, suppl, 1998.

Daly BD, Keay S, **Bartlett ST**. CT features of (PTLD) in renal and/or pancreas transplants.

1. DelaTorre AN, Kuo PC, **Bartlett ST**. Islet-splenocyte cotransplantation in the non-obese diabetic (NOD) mouse. Diabetes 47:1318, suppl, 1998.
2. Philosophe B, Taylor JP, Schweitzer EJ, Farney AC, Colonna JO, Jarrell B, **Bartlett ST**. The superiority of portal venous drainage over systemic venous drainage in solitary pancreas transplantation.
3. Dunkin BJ, Cho ES, Turner J, Jacobs SJ, **Bartlett ST**, Flowers JL. On-call laparoscopic live donor nephrectomy is a viable alternative for urgent renal transplantation. Surg Endos 1999; 13:S31.
4. Schweitzer EJ, Wilson J, Fox M, Fernandez-Vina M, Hunter J, Mann D, Farney AC, Philosophe B, JO Colonna, **Bartlett ST**. A high PRA rescue protocol for crossmatch positive LD kidney transplants. American Society of Transplant Surgeons, May 19-24, 1999. Transplantation 67(9):13, 1999.
5. Philosophe B, Taylor JP, Schweitzer EJ, Farney AC, Colonna JO, Jarrell BE, **Bartlett ST**. Portal venous drainage in pancreas transplantation. Is there an immunologic advantage? Transplantation 67(9):92, 1999.
6. Schweitzer EJ, Wiland A, Goldstein R, Farney A, Philosophe B, Colonna JO, Jarrell BE, **Bartlett** **ST**. Comorbid conditions as preoperative predictors for high cost of live donor kidneytransplantation. Transplantation 97(9):82, 1999.
7. **Bartlett ST**, Evans D, Wilson J, Heron L, Wiland A, Farney AC, Philosophe B, Colonna JO, FinkJ, Jarrell BE, Schweitzer EJ. Results of 295 laparoscopic live donor kidney transplants at one institution. Transplantation 67(9):129, 1999.
8. Lal T, Philosophe B, Schweitzer EJ, Farney AC, Colonna JO, Jarrell BE, **Bartlett ST**. The use of the kidney perfusion pump as a diagnostic and therapeutic tool to utilize marginal cadaveric kidneys. Transplantation 67(9):165, 1999.
9. Wei C, Song H, Seta K, Kinjo M, Lau P, Fink JC, Drachenberg CB, Papadimitriou J, **Bartlett ST**, Weir MR. Chronic cyclosporine reduction decreases apoptosis and p53 expression in human renal biopsies with improvement of renal pathological score and renal function. Transplantation 67(9):178, 1999.
10. Weir MR, Fink JC, Hanes DS, Traver M, Young C, Schofield K, Blahut S, Klassen DK, Cangro CB, Schweitzer EJ, **Bartlett ST**. Chronic allograft nephropathy: Effect of cyclosporine reduction and addition of mycophenolate on progression of renal disease. Transplantation 67(9):302, 1999.
11. Roskopf JA, Fink JC, Wiland A, Blahut S, **Bartlett ST**, Weir MR. Influence of age and race on the time to first acute rejection in cadaveric renal transplant (CRT) recipients in the mycophenolate mofetil (MMF) era. Transplantation 67(7):561, 1999.

Stephen Thomas Bartlett, M.D. Page 38



1. Klassen DK, Fink JC, Blahut SA, Cangro CB, Light PL, Nogueira JM, Hanes DS, **Bartlett ST**, Weir MR. Post-transplant hyperglycemia in pancreas transplant recipients under primary tacrolimus immunosuppression. Transplantation 67(7):659, 1999.
2. Drachenberg CB, Klassen DK, Wiland A, Weir MR, Fink JC, Cangro CB, Blahut S, **Bartlett ST**, Papadimitriou JC. Islet cell damage associated with tacrolimus and cyclosporine. Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 67(7):810, 1999.
3. Drachenberg CB, Beskow CO, Papadimitriou JC, Cangro CB, Rocca M, Klassen DK, Weir MR,

Fink JC, Hanes DS, Wali R, **Bartlett ST**. Human polyoma virus infected cells (PoVIC): Incidence in renal biopsies (BX), urine cytology and correlation with clinical presentation. Transplantation 67(7):843, 1999.

1. Hanes DS, Wali R, Fink JC, Klassen DK, Cangro CB, **Bartlett ST**, Weir MR,. Comparison of the incidence of acute rejection in simultaneous pancreas-kidney transport recipients receiving either tacrolimus (FK506) OR cyclosporine microemulsion (Neoral) in combination with mycophenolate mofetil (MMF) and corticosteroids. Transplantation 67(7):869, 1999.
2. Song H, Seta K, Kinjo M, Lau P, Fink JC, Drachenberg CB, Papadimitriou J, **Bartlett ST**, Weir MR, Wei C. Decreasing expression of transforming growth factor-beta in human renal biopsies with improvement of renal pathological score and renal function following chronic cyclosporine reduction. Transplantation 67(7):920, 1999.
3. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Weir MR, Fink JC, Cangro CB, Light PD, Ramos E, **Bartlett ST**. Histological morphology of colitis associated with mycophenolate mofetil (MMF) in renal allograft recipients: Acute graft versus host disease (GVH) like features. Transplantation 67(7):997, 1999.
4. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, **Bartlett ST**. FK506 (F) and cyclosporine ( C) toxicity in beta cells of pancreas transplant biopsies: Light microscopic (LM), immunohistochemical (IH) and ultrastructural morphology (BM). Lab Inv 79(1):971, 1999.
5. **Bartlett ST**, Jarrell B, Schweitzer EJ, Jacobs S, Wilson J. Increased rates of donation withlaparoscopic donor nephrectomy. American Surgical Association, April 6-8, 2000.
6. Philosophe B, Jarrell B, Schweitzer EJ, Farney AC, Colonna JC, **Bartlett ST**. The superiority of portal venous drainage over systemic enteric drainage in solitary pancreas transplantation. American Surgical Association, April 6-8, 2000.
7. Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Weir MR, **Bartlett** **ST**. Cost effective measures to administer thymoglobulin for induction therapy in pancreastransplant recipients. ASTS/AST, Chicago, May 13 – 17, 2000. Transplantation 69(8):1135, suppl, 2000.
8. Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Weir MR, **Bartlett** **ST**. Experience with thymoglobulin induction therapy in pancreas transplant recipients.ASTS/AST, Chicago, May 13 – 17, 2000. Transplantation 69(8):1136, suppl, 2000.
9. Okitsu T, Farney AC, Hadley GA, **Bartlett ST**. Synergistic allo-and autoimmune destruction of major and minor histoincompatible islet transplants in the non-obese NOD mice. ASTS/AST, Chicago, IL, May 13 – 17, 2000. Transplantation 69(8):1008, suppl, 2000.

Stephen Thomas Bartlett, M.D. Page 39



1. Ramos E, Farney AC, Drachenberg CB, Papadimitriou JC, Wali R, Blahut S, **Bartlett ST**. Outcome of renal transplantation in recipients over the age of 60. ASTS/AST, Chicago, IL , May 13 – 17, 2000. Transplantation 69(8):865, suppl, 2000.
2. Philosophe B, Fink JC, Wiland AM, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE, Krishnamurthi V, **Bartlett ST**. Low kidney rejection rates with basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function. ASTS/AST, Chicago, IL, May 13 – 17, 2000. Transplantation 69(8):569, suppl, 2000.
3. Krishnamurthi K, Farney AC, Philosophe B, Schweitzer E, Colonna JO, Jarrell BE, Krishnamurthi V, **Bartlett ST.** Solitary pancreas re-transplantation with portal venous drainage. ASTS/AST, Chicago, IL, May 13 – 17, 2000.
4. Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Weir MR, **Bartlett** **ST**. A pharmoeconomic analyses of basiliximab in cadaveric renal transplant patients with delayedgraft function. ASTS/AST, Chicago, IL, May 13 – 17, 2000. Transplantation 69(8):20, suppl, 2000.
5. Schweitzer E, Wilson J, Fernandez-Vina M, Fox M, Farney AC, Philosophe B, Colonna J, Jarrell B, **Bartlett ST**. **Abstract #P0269.** A Desensitization Protocol To Enable X-Match Positive LD Kidney Transplants. XVIII International Congress of the Transplantation Society, Rome, August 27-September 1, 2000.
6. Wiland A, Fink JC, Farney AC, Schweitzer EJ, Weir MR, **Bartlett ST**. **Abstract #P0898**. Thymoglobulin Induction Therapy In Pancreas Transplant Recipients. XVIII International Congress of the Transplantation Society, Rome, August 27-September 1, 2000.
7. Wiland A, Fink JC, Farney AC, Schweitzer EJ, Weir MR, **Bartlett ST**. **Abstract #P1050.** Cost Effective Measures To Administer Thymoglobulin For Induction Therapy. XVIII International Congress of the Transplantation Society, Rome, August 27-September 1, 2000.
8. Philosophe B, Fink JC, Wiland AM, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE, Krishnamurthi V, **Bartlett ST**. **Abstract #0115.**Low Kidney Rejection Rates With Basiliximab Induction And Delayed Introduction Of Tacrolimus For Patients With Delayed Graft Function. XVIII International Congress of the Transplantation Society, Rome, August 27-September 1, 2000.
9. Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE, Krishnamurthi V, Wiland AM, **Bartlett ST**. **Abstract #0330.** The Superiority Of Portal Venous Drainage Over Systemic Venous Drainage In Solitary Pancreas Transplantation. XVIII International Congress of the Transplantation Society, Rome, August 27-September 1, 2000.
10. Farney AC, Schweitzer EJ, Chen R, Wiland A, Philosophe B, Colonna J, Jarrell B, **Bartlett ST**. **Abstract #0333.** An SPLK Is Better Than The Sum Of Its Parts. XVIII International Congress ofthe Transplantation Society, Rome, August 27-September 1, 2000.
11. Okitsu T, Farney AC, Hadley G, **Bartlett ST**. **Abstract #0489.** Recurrent Autoimmunity Accelerates Destruction Of Minor And Major Histo-incompatible Islet Grafts In Non-obese

Stephen Thomas Bartlett, M.D.



Page 40

Diabetic (NOD) Mice. XVIII International Congress of the Transplantation Society, Rome, August 27-September 1, 2000.

1. Li C, Dunkin BJ, Cho ES, **Bartlett ST**, Flowers JL. The yield of lower endoscopy in the symptomatic solid organ transplant patient. Surg Endosc 2000; 14:S200.
2. Li C, Dunkin BJ, Keay SK, Cho ES, Liao PS, **Bartlett ST**, Jarrell BE, Flowers JL. Helicobacter pylori in solid organ transplant patients: is the incidence and association with peptic ulcer disease different from the general population? Gastro Endosc 51(4):4719,2000.
3. Li C, Dunkin BJ, Keay SK, Cho ES, Evans D, **Bartlett ST**, Liao PS, Jarrell BE, Flowers JL. The role of espoghagogastroduoenoscopy in diagnosing opportunistic upper gastrointestinal infection in the solid organ transplant recipient. Gastro Endosc 2000; AB222.
4. Wiland AH, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Weir MR, **Bartlett** **ST**. A pharmacoeconomic analyses of basiliximab in cadaveric renal transplant patients withdelayed graft function. Transplantation 69(8):20 , suppl, 2000.
5. Hankey KG, Drachenberg CB, Papadimitriou JC, Klassen DK, **Bartlett ST**, Groh V, Spies T, Mann DL. MICAB/MICB expression in renal transplants. Transplantation 69(8):120, suppl, 2000.
6. Weir MR, Traver-Ward M, Blahut S, Klassen DK, Cangro C, **Bartlett ST**, Fink JC. The long term impact of calcineurin inhibitor reduction or discontinuation in patients with declining kidney function due to chronic allograft nephropathy. Transplantation 69(8):191, suppl, 2000.
7. Gutierrez M, Muth B, Osowski L, Wilson J, Wyland A, Fox M, Schweitzer EJ, **Bartlett ST**, Fernandez-Vina M. Monitoring the removal of donor specific HLA class I antibodies in alloimmunized patients awaiting living donor kidney transplantation. Transplantation 69(8):227, suppl, 2000.
8. Krishnamurthi V, Farney AC, Philosophe B, Schweitzer EJ, Colonna JO, **Bartlett ST**. Solitary

pancreas re- transplantation with portal venous drainage. Transplantation 69(8):375, suppl, 2000.

1. Chareandee C, Drachenberg CB, Weir MR, **Bartlett ST**, Hadley GA. CD103+ T cells that infiltrate rejection clinical renal allografts preferentially home to the graft epithelium. Transplantation 69(8):421, suppl, 2000.
2. Schweitzer EJ, Farney C, Chen R, Wiland A, Philosophe B, Colonna JO, Jarrell BE, **Bartlett ST**.

SPLK transplants: The ‘L’ means lower cost. Transplantation 69(8):610, suppl, 2000.

1. Ramos E, Drachenberg CB, Papadimitriou JC, Wali R, Blahut S, **Bartlett ST**. Posttransplant polyoma virus interstitial nephritis: Progression of allograft dysfunction. Transplantation 69(8):1054, suppl, 2000.

Stephen Thomas Bartlett, M.D. Page 41



1. Qixin S, Wang D, Bingamon A, Farber D, Hadley G, **Bartlett ST**. A no el strategy for abrogation of recurrent autoimmune destruction of islet transplants. American Transplant Congress. 12/3/03.
2. **Bartlett ST.** Role of the Integrin CE103 in Promoting Destruction of Renal Allografts by CD8+T Cells. 01/04.
3. Donghua W, Rongwen Y,Feng Y, El-Asady R, Farber, D, Gress R, Lucas, P, Hadley, G, **Bartlett** **ST**. Regulation of CD103 Expression by CD8+ T Cells Responding to Renal Allografts.Journal ofImmunology. 01/04.
4. Feng Y, Want D, Yuan R, Parker C, Farber D, Hadley G, **Bartlett ST**. CD103 Expression is Required for Destruction of Pancreatic Islet Allografts by CD8+ T Cells. Journal of Experimental Medicine. 01/04.
5. Leeser DB, Bingaman A.W, Poloakova L, Shi Q, Gage F, **Bartlett ST**, Farney AC. Pulsatile Pump Perfusion of Pancreata Before Human Islet Cell Isolation. Transplantation Proceedings. 04/04.

**INVITED LECTURES**

1. **Bartlett ST**. The in vitro perfused pancreas: A model for rigorous comparison of pancreatictransplant techniques. 22nd Meeting Pancreas Club, May 16, 1988.
2. **Bartlett ST**. The in vitro perfused pancreas: A model for rigorous comparison of pancreatictransplant techniques. Pancreas Club Meeting, Washington, DC, May 15, 1989.
3. **Bartlett ST**. HLA matching in renal transplantation. Visiting Professor, University of Medicineand Denistry of New Jersey. Dept. of Medicine, 1993.
4. **Bartlett ST**. Pancreas transplantation. Delaware Medical Society, 1993.
5. **Bartlett ST**. Pancreas transplantation. Visiting Professor, University of Arizona, Dept. of Surgery,1994.
6. **Bartlett ST**. Update on kidney and pancreatic transplants. Visiting Professor. Jersey ShoreMedical Center. May 12, 1994.
7. **Bartlett ST**. Pancreas transplantation: Long term benefits. Invited presentation. Cybercongress.Washington, DC. November 13-15, 1995.
8. **Bartlett ST**. Advances in renal transplantation. Delaware Medical Society, January 23, 1996.
9. **Bartlett ST**. Autoimmune destruction of allografted islets. Invited commentary. Artificial InsulinDelivery Systems, Pancreas and Islet Transplantation, Igls, Austria, January, 1996.
10. **Bartlett ST**. Visiting Professor. University of Giessen, Department of Medicine. Giessen,Germany, January 30, 1996.

Stephen Thomas Bartlett, M.D. Page 42



1. **Bartlett ST**. JMT Finney Memorial Lecture - Transplants - the Wave of the Future? MarylandMedical and Chirurgical Faculty of Maryland. April, 1996
2. **Bartlett ST**. Visiting Professor. Pancreas transplantation: Long term benefits. WashingtonHospital Center. March, 1996.
3. **Bartlett ST.** Equivalent Success of Simultaneous Pancreas Kidney & Solitary PancreasTransplantation: A Prospective Trial of Tacrolimus Immunosuppression With Percutaneous Biopsy. American Surgical Association, Phoenix, Arizona. April 18-23, 1996.
4. **Bartlett ST**. Visiting Professor. Recurrent autoimmunity in islet transplants. University ofMinnesota. May 9, 1996.
5. **Bartlett ST**. Prevention of autoimmune islet allograft destruction by engraftment of donor T cells.American Society of Transplant Surgeons, Dallas, Texas. May 28-31, 1996.
6. **Bartlett ST**. Visiting Professor. The islet transplant paradox. Medical School of Wisconsin.Milwaukee, Wisconsin. August 21, 1996.
7. **Bartlett ST**. Simultaneous pancreas-kidney transplantation - A comparison of enteric and bladderdrainage of exocrine pancreatic secretion. XVI International Congress of the Transplant Society. Barcelona, Spain. August 25-30, 1996.
8. **Bartlett ST**. Sutherland DER. Contemporary Surgery Symposium entitled, “PancreasTransplantation” San Francisco, California. American College of Surgeons Meeting. October 10, 1996
9. **Bartlett ST**. Visiting Professor. “Paradoxical difference in outcome of pancreas and islettransplantation” Duke University Medical Center. Durham, North Carolina. November 6, 1996.
10. **Bartlett ST**. Visiting Professor. “Paradoxical difference in outcome of pancreas and islettransplantation” Temple University Hospital. Philadelphia, Pennsylvania. February 28, 1997.
11. **Bartlett ST**. Visiting Professor. “Prevention of Autoimmune recurrence in islet transplants”.

University of Chicago, Department of Surgery. Chicago, Illinois. March 20, 1997.

1. **Bartlett ST**. Visiting Professor. “Paradoxical difference in outcome of pancreas and islettransplantation” Mt. Sinai Hospital, Department of Surgery. Mt. Sinai, New York. May 5, 1997.
2. **Bartlett ST**. Visiting Professor. International Pancreas Meeting. Milan, Italy. June 7, 1997.
3. **Bartlett ST**. Visiting Professor. “Laparoscopic donor nephrectomy for transplantation” and “New

immunosuppressive agents for pancreas transplantation”.Northwestern University Medical

School. Chicago, Illinois. July 10, 1997.

1. **Bartlett ST**. Visiting Professor. “Long term Cell-cept use”. Roche Pharmaceuticals TrainingSession. Nutley, New Jersey. July 15, 1997.
2. **Bartlett ST**. Visiting Professor. “The paradoxical difference in outcome of pancreas and islettransplants: Evidence from the BB rat and NOD mouse”. University of California at Davis,

California. July 18, 1997.

Stephen Thomas Bartlett, M.D. Page 43



1. **Bartlett ST**. Visiting Professor. “The paradoxical difference in outcome of pancreas and islettransplants: Evidence from the BB rat and NOD mouse”. Mayo Clinic, Minnesota. July 31, 1997.
2. **Bartlett ST**. Invited lecture. “The status of solitary pancreas transplantation”. International

Pancreas Islet Transplant Association. Milan, Italy. September 22-27, 1997.

1. **Bartlett ST**. Invited lecture. “Laparoscopic Living Donor Kidney Transplants” University of

Cincinnati. June 2, 1998.

1. **Bartlett ST**. Invited lecture. “Laparoscopic Nephrectomy:

Resource Networks Clinical Conference. Minneapolis, MN.

An Option for the Donor” United September 14, 1998.

1. **Bartlett ST**. Invited lecture. “Laparoscopic living donor nephrectomy” Deaconess Hospital,

Boston, MA. October 13, 1998.

1. **Bartlett ST**. Invited lecture. “Pancreas Transplantation” Kyoto University, Osaka, Japan. October

26-30, 1998.

1. **Bartlett ST**. Invited lecture. “Innovative approaches to the organ donor shortage”. United

Resource Networks Conference. Scottsdale, AR. November 16, 1998.

1. **Bartlett ST**. Invited lecture. Fujisawa USA, Inc. Beijing, Ghangzhou, Shanghai, China. January

25-29,1999.

1. **Bartlett ST**. Invited lecture. “Laparoscopic living donor nephrectomy”. Rhode Island Hospital,

Providence, RI. March 5, 1999.

1. **Bartlett ST**. Invited lecture. “Laparoscopic living donor nephrectomy” and “PancreasTransplantation and Islet transplantation for diabetes”. Fletcher Allen Medical Center, University of Vermont, Burlington, Vermont. March 26, 1999.
2. **Bartlett ST**. Invited lecture. “Living donor kidney transplantation“. Havana University, Havana,

Cuba. May 9-12, 1999.

1. **Bartlett ST**. Invited lecture. “Laparoscopic nephrectomy provides good quality kidneys”.

American Society for Transplantation. Chicago, IL. May 19, 1999.

1. **Bartlett ST**. “Pancreas Transplantation”. International Pancreasand Islet Transplant Association.Sydney, Australia. August 13, 1999.
2. **Bartlett ST**. “Pancreas Transplantation”. Keynote speaker: Japanese Society for Transplantation.Tsukuba, Japan. September 16, 1999.
3. **Bartlett ST**. Invited lecture. “Pancreas Transplantation”. Hartford, Connecticut. October 25,

1999.

1. **Bartlett ST**. Invited lecture. Israel Penn Symposium. Scottsdale, Arizona. October 28, 1999.
2. **Bartlett ST**. Invited lecture. “Pancreas Transplantation” and “Laparoscopic Donor Nephrectomy”.

United Resource Network. Scottsdale, Arizona. March 2-3, 2000.

1. **Bartlett ST**. Invited lecture. “Pancreas Transplantation” and Laparoscopic Donor Nephrectomy.

The 8th Asian Pacific Congress of Nephrology. Taipei, Taiwan.. March 26-30, 2000.

Stephen Thomas Bartlett, M.D. Page 44



1. **Bartlett ST**. Invited lecture. “Increased rates of donation with laparoscopic donor nephrectomy”.

American Surgical Association. Philadelphia, PA. April 7, 2000.

1. **Bartlett ST**. “Pancreas Transplantation”. Scientific Meeting of the Transplantation Society ofAustralia and New Zealand. Canberra, Australia. April 12, 2000.
2. **Bartlett ST**. Invited lecture. American Society of Transplantation. May 13–17, 2000.
3. **Bartlett ST**. Invited lecture “Living Donor Organ Transplantation: A National ConsensusConference. National Kidney Foundation. Kansas City, MO. June 1, 2000.
4. **Bartlett ST**. Invited lecture. “Management of the outpatient renal transplant recipient

Conference. SUNY Hospital, Brooklyn, NY. June 2, 2000.

1. **Bartlett ST**. Invited Debate. “Pancreas/Islet transplant versus intensive insulin management inthe non-uremic patient”. Mt. Sinai Hospital, New York, NY. October 17, 2000.
2. **Bartlett ST**. Invited lecture. “Low kidney rejection rates with Basiliximab induction anddelayed introduction of tacrolimus for patients with delayed graft function”. Scottsdale, AZ.

November 9, 2000.

1. **Bartlett ST**. Invited lecture. “Organ donation and transplantation”. TRC Conference.

Peninsula Regional. Salisbury, MD. December 19, 2000.

1. **Bartlett ST**.Invited lecture. “Increased rates of donation with laparoscopic donornephrectomy”. SEOPF Scientific Session. Tampa, FL. January 18, 2001.
2. **Bartlett ST**. Invited lecture. “Increased rates of donation with laparoscopic donornephrectomy” and “Type I diabetes: treatment vs. cure”. University of Cincinnati Medical

Center. Cincinnati, OH. January 23 – 24, 2001.

1. **Bartlett ST**. Invited lecture. “Increased rates of donation with laparoscopic donornephrectomy”. Cleveland Clinic Foundation. Cleveland, OH. March 12, 2001.
2. **Bartlett ST**. Invited lecture. “Physiological & immunological advantages of portal drainage ofthe pancreas graft”. International Pancreas & Islet Transplant Association. Innsbruck, Austria.

June 12, 2001.

1. **Bartlett ST**. Invited lecture. “ New trend of immunosuppressive therapy in kidneytransplantation and pancreas transplantation“. Scientific Meeting of Transplantation Society of

ROC at Chang Gang Memorial Hospital. Taiwan. June 25 – 29, 2001.

1. **Bartlett ST**. Invited lecture. “Laparoscopic donor nephrectomy for renal transplantation“.Hawaii Surgical Association Meeting. Queen’s Hospital. Honolulu, Hawaii. August 3-5, 2001.
2. **Bartlett ST**. Invited lectures. “How I Do It: Kidney & Pancreas” and “Debate: Laparoscopic

Nephrectomy”. Transplant Immunosuppression 2001: The Compleat Care of the Transplant

Recipient. Minnesota, MN. October 24 – 27, 2001.

1. **Bartlett ST**. American Society of Transplant Surgeons Annual Conference. June 2, 2003
2. **Bartlett ST**. Seminar - FDA Clinical Trial Requirements, Pittsburgh, PA , June 25, 2003

Stephen Thomas Bartlett, M.D. Page 45



1. **Bartlett ST**. Invited speaker for Norvartis in Newark, NJ.“New Advances inPancreas IsletTransplantation” July 1, 2003.
2. **Bartlett ST**. Invited lectures. 9thCongress of the International Pancreas & Islet Transplant

Association, Dublin, Ireland. “Abrogation of Autoimmune Recurrence in the NOD Mouse” July

8 – 11, 2003.

64. **Bartlett ST**. Invited lectures. University of Pennsylvania - Philadelphia,“Abrogation ofAutoimmune Recurrence in the NOD Mouse” August 1, 2003

1. **Bartlett, ST**. Invited lectures. “Pancreas Transplantation.” Harvard University, Massachusetts

General Hospital. September 2003.

1. **Bartlett ST**. Invited lectures. Texas A&M,“Abrogation of Autoimmune Recurrence in the NOD

Mouse” September 3, 2003

1. **Bartlett ST**. Invited lectures. “Transplantation in the New Millennium”, Rancho Mirage, CA.“Abrogation of Autoimmune Recurrence in the NOD Mouse” September 12-13, 2003.
2. **Bartlett ST**. Invited lectures. Chicago, IL“Abrogation of Autoimmune Recurrence in the NOD

Mouse” October , 20, 2003.

1. **Bartlett ST**. Invited lectures. Guest Speaker, Emory University. “Abrogation of AutoimmuneRecurrence in the NOD Mouse” October , 21, 2003
2. **Bartlett ST**. Seminar -“Working with the IACUC: Writing an Animal Protocol” October 29,

2003.

1. **Bartlett ST**. Invited lectures. Symposium on Transplant Pathology, La Coruna, Madrid, Spain.

“Abrogation of Autoimmune Recurrence in the NOD Mouse” October 30-31, 2003.

1. **Bartlett ST**. Grand Rounds, St. Agnes Hospital.“Pancreas and Islet Transplantation”

November 6, 2003.

1. **Bartlett ST**. Invited lectures.“Renal transplantation in patients with hemolytic uremicsyndrome.” National Kidney Foundation, Dallas, TX. December 3-4, 2003.
2. **Bartlett, ST**. Invited lectures. ASTS Winter Symposium. The Case for Solitary PancreasTransplantation. Scottsdale, AZ. January 23-25, 2004.
3. **Bartlett, ST**. Invited lectures. 5thAnnual Emerging Technologies & Innovative Approached forManaging Patient with Complex Medical Conditions. New Orleans, LA. 02/04/04.
4. **Bartlett, ST**. Invited lectures. NIH Endocrine Grand Rounds.“Type I Diabetes: Treatment vs.Cure.” Bethesda, MD. 04/09/04.
5. **Bartlett ST.** Invited Lecture. Vascular Access for Hemodialysis. “End Stage Access Salvage.”

Lake Buena Vista, FL. May 7, 2004.

1. **Bartlett ST.** Invited Lecture. American Diabetes Association 64thScientific Sessions. “What’sNew in Pancreas Transplantation.” Orlando, FL. June 7, 2004.
2. **Bartlett ST.** Invited Lecture. XX International Congress of the Transplantation Society.

“Transplantation for Type II Diabetes” Vienna, Austria. September 9, 2004.

Stephen Thomas Bartlett, M.D. Page 46



1. **Bartlett ST.** Invited Lecture. University of Maryland Medical Center Shock Trauma CenterGrand Rounds. “Pancreatic and Islet Transplantation”. Baltimore, MD. January 20, 2005.
2. **Bartlett ST.** Invited Lecture. IPITA. “Chronic Allograft Rejection: The Next Challenge ForPancreas Transplantation.” Geneva, Switzerland. May 5, 2005.
3. **Bartlett ST.** Invited Lecture. St. Agnes Health Care Grand Rounds. “Pancreatic and IsletTransplantation”. Baltimore, MD. November 30, 2005.
4. **Bartlett ST.** Invited Lecture. Bulgarian Transplant Symposium at the Military Medical Academy.

“Beginning a Pancreas Transplant Program.” Sofia, Bulgaria. November 29, 2006.

1. **Bartlett ST.** Grand Rounds Speaker. University of Kansas Medical Center. “Pancreas and IsletTransplantation.” Kansas City, MO. September 19, 2006.
2. **Bartlett ST.** Invited Speaker. Innovations in the Management of Kidney Disease Conference.

“Strategies for Reducing Elevated Panel Reactive Antibodies (PRAs) in Patients Awaiting Deceased Donor Kidney Transplantation.” United Resource Networks, Minneapolis, Minnesota.

July 19, 2006.

1. **Bartlett ST.** Invited Lecture. Radisson University Hotel. “The University of Minnesota Salutes40 Years of Pancreas Transplantation: An International Collaboration.” Minneapolis, Minnesota.

December 8-9, 2006.

1. **Bartlett ST**. Invited Lecture. The Royal Society of Medicine. “Nine Years Experience withDesensitization of Living Donor Transplant Recipients”. London, England. June 1, 2007.
2. **Bartlett ST**. Invited Speaker. CTS IPITA IXA and The Transplantation Society Meeting.

“Autoimmune Recurrence in Experimental Models of Islet Transplantation.” Minneapolis, MN.

September 15-20, 2007.

1. **Bartlett ST.** Invited Speaker. The Transplantation Society–New Key Opinion Leader Meeting2007. “Early Withdrawal of Calcineurin Inhibitors in Renal Transplant Recipients with Moderate to Severe Renal Dysfunction”. Cape Town, South Africa. November 15-18, 2007.
2. **Bartlett, ST.** Invited Speaker. U.S. Secretary of Health & Human Services’ Advisory Committeeon Organ Transplantation (ACOT). “Update on Kidney Disease Outcome Quality Initiative/Early Kidney Transplantation Conference.” Rockville, MD. May 5, 2008.
3. **Bartlett, ST.** Invited Speaker. ASTA and AST Joint Meeting. “Composite Tissue Allografts:Challenges and Opportunities.” Toronto, Canada. May 31, 2008 – June 4, 2008.
4. **Bartlett, ST.** Invited Speaker. The Transplantation Society meeting.“Pancreas: Symposium 1:What is the Optimal Use of the Donor Pancreas?” on the topic “Is there a role for pancreas transplantation for Type II diabetics.” Sydney, Australia. August 10-14, 2008.
5. **Bartlett, ST.** Grand Rounds Speaker. Marshall University– Joan C. Edwards School of Medici.”Pancreas Transplantation. Huntington, WV. October 15, 2008.
6. **Bartlett, ST.** Invited International Faculty and Panel Discussion Moderator for AO North Americacourse entitled “State of the Art Facial Reconstruction.” Hyatt Regency Baltimore on the Inner

Harbor. Baltimore, MD March 12, 2009.

Stephen Thomas Bartlett, M.D. Page 47



1. **Bartlett, ST.** Visiting Professor. University of Texas Health Science Center. “CompositeTissueTransplantation.” San Antonio, TX. March 30, 2009.
2. **Bartlett, ST.** Invited Lecture. Distinguished Graduate Julius Mackie Lecturer. University of

Pennsylvania School of Medicine. “Composite Tissue Transplantation.” Philadelphia, PA May 21, 2009.

1. **Bartlett, ST.** Invited Lecture. Annual Battistella Memorial Lectureship. University of California,

David School of Medicine. “Composite Tissue Transplantation.” Sacramento, CA. September 11-12, 2009.

1. **Bartlett, ST.** Grand RoundsSpeaker, Union Memorial Hospital. “Pancreas and Islet CellTransplant”. Baltimore, MD. April 8, 2010.
2. **Bartlett, ST**. Grand Rounds Speaker, Massachusetts General Hospital. “Composite Tissue Allo-transplantation.” Boston, MA. June 7, 2010
3. **Bartlett, ST.** Invited Speaker. The XXIII Transplantation Society meeting. “Results of PancreasTransplantation in 2010. The case for prioritized allocation to islet transplantation.” Vancouver,

Canada. August 15-19, 2010.

1. **Bartlett, ST**. Grand Rounds Speaker. University of Maryland Medical Center, Department ofAnesthesiology

Composite Tissue Transplantation. Baltimore, MD. August 26, 2010.

1. **Bartlett, ST**. Invited Speaker. “Frankenstein: Penetrating the Secrets of Nature” exhibit at the

Health Sciences Library, University of Maryland Baltimore, Baltimore, MD December 14, 2010

1. **Bartlett, ST**. Invited Speaker. “IPITTA President’s Report”. The Transplantation Society

Meeting, Prague, Czech Republic, May 1, 2011.

1. **Bartlett, ST** Invited Speaker, University of Pennsylvania, September 22, 2012, Clyde BarkerSymposium, “Experimental and Clincal Craniofacial Transplantation”.
2. **Bartlett, ST** Invited Speaker, West Virginia Health Center, Morgantown, West Virginia,February 2013, Grand Rounds Presentation. “Craniofacial Transplantation: Implications for Transplant Tolerance”

|  |  |  |
| --- | --- | --- |
| 106. | **Bartlett, ST** | Invited Speaker, John Radcliffe Hospital, Oxford, UK. April 2013. Grand |
|  | Rounds Presentation. “Experimental and Clinical Face Transplantation” | |

1. **Bartlett ST** Visiting Professor. Annual Resident Research Symposium, University ofWisconsin, May, 2013. “Clinical and Experimental Craniofacial Transplantation, Toward Tolerance with Vascularized Bone”.
2. **Bartlett, ST** Invited Speaker, Francis D. Moore Surgical Lecture. Walter Reed NationalMilitary Medical Center, July 2013. “Experimental and Clinical Face Transplantation”
3. **Bartlett, ST** Invited Speaker, Department of Medicine Grand Rounds, University of MarylandSchool of Medicine, September, 2013. “Experimental and Clinical Face Transplantation”

Stephen Thomas Bartlett, M.D. Page 48



1. **Bartlett, ST**Invited Speaker, Johns Hopkins University Grand Rounds, October, 2013.

“Experimental and Clinical Face Transplantation”

1. **Bartlett, ST** Invited Speaker, University of Maryland School of Medicine Festival of Science,November, 2013
2. **Bartlett, ST**Invited Speaker, Massachusetts General Hospital Grand Rounds, December 2013.

“Pancreas and Islet Transplantation.”

1. **Bartlett, ST**Invited Speaker, Massachusetts General Hospital Surgical Grand Rounds,

December 2013. “Single Port Laproscopic Living Donor Nephrectomy.”

|  |  |  |
| --- | --- | --- |
| 114. | Bartlett ST | Surgical Grand Rounds. St. Agnes Hospital March, 2018 “Face Transplantation” |
| 115. | Bartlett ST | George Zuidema Lecture. Johns Hopkins Hospital “Cardiac Xenotransplantation” |
|  | May 31, 2018 | |